IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene MLANA Ensembl ENSG00000120215 Chromosome 9 Start 5880908 End 5899822
Description Melanoma antigen recognized by T-cells 1 (MART-1)(Melan-A protein)(Antigen SK29-AA)(Antigen LB39-AA) [Source:UniProtKB/Swiss-Prot;Acc:Q16655]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :
     HGNC : 7124
     Entrez Gene : 2315
     UCSC : uc003zjo.1
     GeneCards : 7124
     RefSeq : NM_005511
     CCDS : CCDS6466.1
     Uniprot : Q16655
     Interpro : Q16655
     OMIM : 605513
     GeneTests : MLANA
     CGAP : MLANA

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1050_at  0.29  2.11e-1  3.05e-1  0.14  6.39e-1  7.27e-1
 HG_U95  1051_g_at  0.26  2.19e-1  3.15e-1  0.52  8.59e-2  1.45e-1
 HG_U95  31889_at  0.46  1.37e-4  5.40e-4  0.68  8.40e-4  2.66e-3
 HG_U133A  206426_at  -0.22  1.07e-1  1.39e-1  1.15  1.36e-12  1.78e-12
 HG_U133A  206427_s_at  0.10  2.78e-1  3.30e-1  0.94  3.24e-20  4.72e-20
 HG_U133_Plus2  206426_at  0.21  2.87e-1  3.74e-1  -0.15  5.39e-1  5.97e-1
 HG_U133_Plus2  206427_s_at  0.39  6.39e-2  1.04e-1  0.84  2.43e-4  5.13e-4
 Stanford  6067  -1.35  2.34e-2  1.11e-1  -0.92  2.11e-1  4.40e-1
 Stanford  6360  0.07  8.41e-1  9.12e-1  0.28  5.02e-1  7.17e-1
 Agilent_HS_21.6K  3218  0.05  8.16e-2  2.04e-1  0.06  1.48e-1  2.76e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  206426_at  -0.03  9.62e-1  9.98e-1  0.74  4.62e-3  1.00e+0
 HG_U133A  206427_s_at  0.10  7.28e-1  9.72e-1  -0.22  4.50e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1050_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1051_g_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 31889_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 206426_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 206427_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 206426_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 206427_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 6067    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 6360    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 3218    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
melan-a melanoma CONTEXT: The monoclonal antibody A103 recognizes an antigen on melanoma cells known as Melan-A or MART-1. 11825112 Human
mart-1 melanoma CONTEXT: The monoclonal antibody A103 recognizes an antigen on melanoma cells known as Melan-A or MART-1. 11825112 Human
mart-1 melanoma Among candidate factors, interferon-gamma (IFN-gamma) (10(2) to 10(3) U/ml) suppressed expression of antigens MART-1, TRP-1, and gp100 by M14 melanoma cells as shown by immunohistology and fluorescence-activated cell sorting analysis, reducing MART-1 expr 11839572 Human
mart-1 tumor Reduced MART-1 expression was frequently observed in adjacent tumor cells. 11839572 Human
melan-a metastatic malignant melanoma OBJECTIVE: To describe the morphologic spectrum of metastatic malignant melanoma (MM) cells involving the breast and to explore the diagnostic utility of HMB45, Mart-1, Melan-A and T311 (antityrosinase) antibodies in fine needle aspiration material of MM 11843553 NA
mart-1 metastatic malignant melanoma OBJECTIVE: To describe the morphologic spectrum of metastatic malignant melanoma (MM) cells involving the breast and to explore the diagnostic utility of HMB45, Mart-1, Melan-A and T311 (antityrosinase) antibodies in fine needle aspiration material of MM 11843553 NA
melan-a melanomas Twenty-one of 28 (75%) melanomas were reactive for Melan-A. 11893035 Human
melan-a tumors Reactivity for Melan-A was detected in 5 of 102 (4.9%) nonmelanomatous tumors. 11893035 Human
melan-a spindle-cell melanomas As with D5, HMB-45 and Melan-A failed to detect all spindle-cell melanomas. 11893035 Human
mart-1 malignant melanoma Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. 11903234 Human
mart-1 melanoma OBJECTIVES: To characterize the molecular profiles of melanoma cells in sentinel lymph nodes employing the mRNA expression of tyrosinase, MIA and MART-1 as markers. 11903234 NA
mart-1 melanoma By T cell receptor clonotypic mapping and staining with tetrameric HLA-peptide complexes, we demonstrate the presence of melanocyte differentiation antigen MART-1 specific T cells in the areas of destruction of both neoplastic and normal melanocytic cells 11918704 Human
mart-1 melanoma Cellular immune responses to melanoma are tightly regulated and include specific T cell responses to self antigens such as Mart-1 and gp100. 11918705 Human
melan-a uveal melanomas DESIGN: Fifteen uveal melanomas (5 spindle, 5 epithelioid, and 5 mixed uveal subtypes) were immunolabeled with a panel of antibodies that included S100, tyrosinase, melan-A, HMB-45 and HMB-50 combination, MITF, and p75NTR. 11934320 Human
melan-a cutaneous melanomas HMB-45, HMB-50, tyrosinase, melan-A, and MITF immunolabeled all uveal melanomas strongly, irrespective of the histologic subtype, but not cutaneous melanomas. 11934320 Human
melan-a uveal melanomas HMB-45, HMB-50, tyrosinase, melan-A, and MITF immunolabeled all uveal melanomas strongly, irrespective of the histologic subtype, but not cutaneous melanomas. 11934320 Human
melan-a tumor Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. 11937585 Human
melan-a melanoma To gain insight into these questions, we performed a functional and structural longitudinal analysis of the TCR of circulating CD8(+) T cells specific for the HLA-A2-restricted immunodominant epitope from the melanocyte differentiation Ag Melan-A in a mel 11937585 Human
mart-1 melanoma AIMS: To detect micrometastases in the sentinel lymph nodes (SLN) of melanoma patients the authors analysed 52 lymph nodes (47 SLNs and five non-sentinel) and 17 corresponding primary skin melanomas using reverse transcriptase-polymerase chain reaction as 11952287 NA
mart-1 melanomas AIMS: To detect micrometastases in the sentinel lymph nodes (SLN) of melanoma patients the authors analysed 52 lymph nodes (47 SLNs and five non-sentinel) and 17 corresponding primary skin melanomas using reverse transcriptase-polymerase chain reaction as 11952287 NA
melan-a tumor The tumor showed strong immunoreactivity with HMB45 antibody and Melan-A. 11979098 Human
melan-a canine melanoma The staining patterns of the monoclonal antibodies S-100 and Melan-A in canine melanoma were assessed based on cytological specimens of six canine melanomas (four benign, two malignant). 12069262 Human
melan-a canine melanomas The staining patterns of the monoclonal antibodies S-100 and Melan-A in canine melanoma were assessed based on cytological specimens of six canine melanomas (four benign, two malignant). 12069262 Human
melan-a canine melanomas The immunocytochemical staining results of the canine melanomas and the regional lymph nodes showed high conformity with the immunohistochemical reactivity patterns for S-100 and Melan-A. 12069262 others
melan-a canine melanoma Melan-A, in particular, may be helpful for the cytological diagnosis of canine melanoma. 12069262 Human
melan-a clear cell sarcoma Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. 12072203 Human
melan-a malignant melanoma Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. 12072203 Human
melan a melanomas Melan A and S100 protein immunohistochemistry in feline melanomas: 48 cases. 12102204 others
melan a melanoma Immunohistochemistry, using a monoclonal antibody to Melan A and a polyclonal antibody to S100 protein, was applied to 48 formalin-fixed, paraffin-embedded specimens of feline melanoma. 12102204 others
melan a tumors Thirty-two tumors (67%) were positive for Melan A and 42 (87.5%) were positive for S100. 12102204 others
melan a tumors All but one of the tumors that were positive for Melan A were also positive for S100. 12102204 others
melan a amelanotic melanomas S100 was detected in 11 of 16 tumors that were negative for Melan A. Seventy-five percent (9 of 12) of amelanotic melanomas were negative for Melan A. 12102204 others
melan a tumors S100 was detected in 11 of 16 tumors that were negative for Melan A. Seventy-five percent (9 of 12) of amelanotic melanomas were negative for Melan A. 12102204 others
melan a tumor Sebaceous adenoma was the only nonmelanocytic tumor examined that reacted with antibody to Melan A. 12102204 others
melan a sebaceous adenoma Sebaceous adenoma was the only nonmelanocytic tumor examined that reacted with antibody to Melan A. 12102204 others
melan a cutaneous melanoma Although less sensitive than S100 protein, Melan A is more specific for melanoma and is useful in differentiating feline cutaneous melanoma from the more common pigmented basal cell tumor. 12102204 others
melan a melanoma Although less sensitive than S100 protein, Melan A is more specific for melanoma and is useful in differentiating feline cutaneous melanoma from the more common pigmented basal cell tumor. 12102204 others
melan a cell tumor Although less sensitive than S100 protein, Melan A is more specific for melanoma and is useful in differentiating feline cutaneous melanoma from the more common pigmented basal cell tumor. 12102204 others
melan-a melanoma A soluble SHPS-1 ligand (CD47-Fc) has now been shown to bind to Melan-a non-tumorigenic melanocytes but not to syngeneic B16F10 melanoma cells. 14739297 Human
mart-1 melanoma Other new antigens for melanoma are NKIC3 and Anti-Melan-A (MART-1). 12140874 Human
mart1 melanoma Exosomes from patients with melanoma deliver Mart1 tumour antigens to dendritic cells derived from monocytes (MD-DCs) for cross presentation to clones of cytotoxic T lymphocytes specific to Mart1. 12147373 Human
mart-1 melanoma This study was performed to detect circulating melanoma cells in peripheral blood using a novel method based on magnetic-activated cell separation (MACS) followed by a nested reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosinase and MART 12170179 NA
mart-1 melanoma Samples to be tested were enriched for tumour cells either by isolating melanoma cells using two anti-melanoma antibodies (MART-1 and HMB-45) or by CD45 depletion of the non-melanoma cell fraction. 12170179 Human
mart-1 tumour Samples to be tested were enriched for tumour cells either by isolating melanoma cells using two anti-melanoma antibodies (MART-1 and HMB-45) or by CD45 depletion of the non-melanoma cell fraction. 12170179 Human
mart1 tumor Tumor cells strongly expressed S100 protein, gp100 (HMB-45), and microphthalmia transcription factor, and variably expressed MART1, but not cytokeratins, CD34, or muscle-specific actin. 12204064 Human
melan-a cutaneous melanomas METHODS: Two hundred thirty-one SNs from 100 consecutive patients with cutaneous melanomas that measured 1-4 mm in thickness were bisected, and half of the lymph node was examined according to an extensive histopathologic protocol involving serial section 15073857 NA
melan-a melanoma Using HLA-A2 peptide tetramers, CD8(+) T cells recognizing the modified Melan-A immunodominant ELAGIGILTV peptide were isolated from four metastatic lesions resected from a single melanoma patient, and their TCR repertoire was studied. 12244204 Human
mart-1 melanoma Immunohistochemistry with antibodies to MART-1 and HMB-45 confirmed that the atypical cells in the ducts of the salivary glands were indeed melanoma cells. 12324791 Human
mart-1 b16 melanoma Previous experience in a model in which C57BL/6 mice immunized with DC transduced with adenoviral vectors expressing MART-1 demonstrated a 20-40% complete protection to a tumor challenge with B16 melanoma cells. 12386826 Mouse
mart-1 tumor Previous experience in a model in which C57BL/6 mice immunized with DC transduced with adenoviral vectors expressing MART-1 demonstrated a 20-40% complete protection to a tumor challenge with B16 melanoma cells. 12386826 Mouse
melan-a melanoma In the present study, we performed a critical analysis of the ability of cytotoxic T-lymphocyte (CTL) clones, derived from two melanoma patients through stimulation with the A27L peptide analogue, to cross-react with the naturally processed Melan-A/MART-1 12394191 Human
melan-a tumors These four tumors lacked vacuolated, neoplastic Leydig cells, and the fat cells in the single case studied were negative for inhibin-alpha and melan-A but positive for S-100. 12409718 Human
melan-a melanoma Importantly, stimulation of PBMC from melanoma patients with the most frequently recognized peptides elicited the expansion of heterogeneous CD8(+) T cell populations, one fraction of which cross-recognized Melan-A. 12421949 Human
melan-a tumor Tumor cells are usually positive for vimentin, S100, neuron-specific enolase, and Melan-A, and negative for cytokeratin. 12450197 Human
melan-a tumour Tumour cells expressed S100, melan-A and neurone-specific enolase but were negative for HMB45. 14534752 Human
mart-1 melanoma In this study, we used the detection of MART-1 and tyrosinase (TYR) mRNA with a quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay to identify circulating melanoma cells. 12459648 NA
mart-1 tumour By comparing the immunohistochemistry results from consecutive biopsies with the RT-PCR results, we demonstrated that patients with MART-1 and TYR protein in their tumour cells had circulating MART-1 and TYR mRNA in 77% and 54% of the cases, respectively. 12459648 Human
melan a melanoma METHODS AND RESULTS: Sentinel lymph nodes (n = 41) from 29 melanoma patients and 29 lymph nodes from 27 patients without melanoma were analysed by histology (H&E) and immunohistology (Melan A, HMB45). cDNA of these lymph nodes was subjected to LightCycler 12460203 NA
melan-a conjunctival melanomas DESIGN: Eleven conjunctival melanomas, including 1 caruncular melanoma, were immunolabeled with a panel of antibodies that included S100, tyrosinase, melan-A, HMB-45 and HMB-50 combination, microphthalmia transcription factor, and p75 neurotrophin recepto 12470134 Human
melan-a melanoma DESIGN: Eleven conjunctival melanomas, including 1 caruncular melanoma, were immunolabeled with a panel of antibodies that included S100, tyrosinase, melan-A, HMB-45 and HMB-50 combination, microphthalmia transcription factor, and p75 neurotrophin recepto 12470134 Human
melan-a conjunctival melanomas Tyrosinase, HMB-45 and HMB-50 combination, melan-A, and microphthalmia transcription factor were expressed at high levels in conjunctival melanomas, whereas p75 neurotrophin receptor was not expressed. 12470134 Human
melan-a melanoma CONCLUSIONS: Melanomas of the conjunctiva, including the caruncle, expressed S100, tyrosinase, melan-A, HMB-45 and HMB-50 combination, and microphthalmia transcription factor at high levels, suggesting that these are good markers for this melanoma subtype 12470134 Human
melan-a melanomas CONCLUSIONS: Melanomas of the conjunctiva, including the caruncle, expressed S100, tyrosinase, melan-A, HMB-45 and HMB-50 combination, and microphthalmia transcription factor at high levels, suggesting that these are good markers for this melanoma subtype 12470134 Human
melan a melanoma Antibody binding to glutaraldehyde-fixed melanoma cells and Melan A melanocytes was assayed using chemiluminescent-enzyme-linked immunosorbent assay (CL-ELISA) for increased sensitivity. 12470474 Human
melan-a melanoma We determined the sensitivity and specificity of 3 novel antibodies (microphthalmia transcription factor [Mitf], Melan-A, and tyrosinase) as markers for melanoma in cytologic preparations and compared the results with those of commonly used markers (S-100 12472287 Human
melan-a malignant neoplasms We stained 72 cell blocks from 40 patients with melanoma and 32 with nonmelanocytic malignant neoplasms with antibodies against S-100, HMB-45, Mitf, Melan-A, and tyrosinase. 12472287 Human
melan-a melanoma We stained 72 cell blocks from 40 patients with melanoma and 32 with nonmelanocytic malignant neoplasms with antibodies against S-100, HMB-45, Mitf, Melan-A, and tyrosinase. 12472287 Human
melan-a tumor Nuclear stainingfor Mitf and cytoplasmic stainingfor S-100, HMB-45, Melan-A, and tyrosinase in more than 10% of tumor cells was considered positive. 12472287 Human
melan-a melanoma Mitf Melan-A, and tyrosinase are sensitive markersfor epithelioid melanoma. 12472287 Human
melan-a melanoma An antibody panel consisting of Mitf and Melan-A is superior to a panel of S-100 and HMB-45 in the diagnosis of melanoma in cytologic specimens. 12472287 Human
mart-1 primary cutaneous malignant melanomas The introduction of a potentially valuable pan-melanoma cocktail, composed of HMB 45, MART-1 and tyrosinase, is examined in 50 primary cutaneous malignant melanomas, five desmoplastic malignant melanomas (DMM), 35 benign naevi, 20 metastatic malignant mel 12572952 Human
mart-1 desmoplastic malignant melanomas (dmm) The introduction of a potentially valuable pan-melanoma cocktail, composed of HMB 45, MART-1 and tyrosinase, is examined in 50 primary cutaneous malignant melanomas, five desmoplastic malignant melanomas (DMM), 35 benign naevi, 20 metastatic malignant mel 12572952 Human
mart-1 squamous cell carcinomas (scc) The introduction of a potentially valuable pan-melanoma cocktail, composed of HMB 45, MART-1 and tyrosinase, is examined in 50 primary cutaneous malignant melanomas, five desmoplastic malignant melanomas (DMM), 35 benign naevi, 20 metastatic malignant mel 12572952 Human
mart-1 metastatic malignant melanomas The introduction of a potentially valuable pan-melanoma cocktail, composed of HMB 45, MART-1 and tyrosinase, is examined in 50 primary cutaneous malignant melanomas, five desmoplastic malignant melanomas (DMM), 35 benign naevi, 20 metastatic malignant mel 12572952 Human
mart-1 basal cell carcinomas (bcc) The introduction of a potentially valuable pan-melanoma cocktail, composed of HMB 45, MART-1 and tyrosinase, is examined in 50 primary cutaneous malignant melanomas, five desmoplastic malignant melanomas (DMM), 35 benign naevi, 20 metastatic malignant mel 12572952 Human
mart-1 melanoma PCR was used to detect melanoma cells that expressed the melanoma-associated antigens MART-1, MAGE-3, tyrosinase and/or gp100 in 91 patients with melanoma. 11092048 Human
mart-1 melanoma The goal was to determine if PCR tests on blood samples for MART-1 and tyrosinase were predictive of recurrence of melanoma in a 2-year follow-up period. 11092049 Human
mart-1 melanoma (PCR assays for MUC-18, p97 and gp100 were positive in blood samples from normal subjects and excluded from the study.) PCR tests for MART-1 and tyrosinase were most commonly positive in the first 3 months following surgical removal of melanoma, and three 11092049 Human
mart-1 melanoma (Positivity rate for tyrosinase in 48 patients with disseminated melanoma was 60.4% compared to 14.6% for MART-1.) Tests for MART-1 and tyrosinase were strongly predictive of disease-free survival (DFS) and were more powerful predictors of DFS than lymph 11092049 Human
mart-1 melanoma We therefore compared the presence of specific mRNA for tyrosinase, gp100, and MART-1 by RT-PCR amplification of specific cDNA from serum, plasma, and whole blood samples of 10 melanoma patients. 11115581 Human
mart-1 melanoma In addition, tyrosinase mRNA could be detected in the serum and/or plasma of 6 of 10 melanoma patients whereas gp100 and MART-1 specific transcripts were not detectable in any of the samples tested. 11115581 Human
mart-1 melanoma We conclude that tyrosinase mRNA but not gp100 and MART-1 mRNA can be amplified from serum and/or plasma in a subset of melanoma patients showing circulating melanoma cells. 11115581 Human
melan-a spindle-cell melanoma The immunohistochemical confirmation of desmoplastic/spindle cell melanoma may also be difficult, because the majority of tumors are negative for specific melanocytic markers such as HMB-45 and Melan-A, despite their usual expression of S-100 protein. 11145252 Human
melan-a tumors The immunohistochemical confirmation of desmoplastic/spindle cell melanoma may also be difficult, because the majority of tumors are negative for specific melanocytic markers such as HMB-45 and Melan-A, despite their usual expression of S-100 protein. 11145252 Human
melan-a desmoplastic melanoma We conclude that the sensitivity and specificity of MiTF for desmoplastic melanoma equals or exceeds that of such markers as HMB-45 or Melan-A, and that MiTF should be part of the initial immunohistochemical panel for the work-up of such cases. 11145252 Human
melan-a angiomyolipoma Angiomyolipoma has a unique immunophenotype with co-expression of muscle-specific actin and melanocytic markers such as HMB-45 and Melan-A. 11145253 Human
melan-a angiomyolipoma Microphthalmia transcription factor showed the most widespread staining in angiomyolipoma (50% of cases staining more than half of the tumor cells) followed by Melan-A (24% of cases staining more than 50%). 11145253 Human
melan-a tumor Microphthalmia transcription factor showed the most widespread staining in angiomyolipoma (50% of cases staining more than half of the tumor cells) followed by Melan-A (24% of cases staining more than 50%). 11145253 Human
melan-a angiomyolipoma We conclude that microphthalmia transcription factor, but not tyrosinase immunostaining, has a sensitivity and specificity that rivals those of the established markers, HMB-45 and Melan-A, in the diagnosis of angiomyolipoma. 11145253 Human
melan-a tumor Our data supports the use of a panel in difficult cases that includes antibodies to microphthalmia transcription factor, either Melan-A or HMB-45, and muscle-specific actin to provide the best mix of high sensitivity, high specificity, nuclear and cytopla 11145253 Human
melan-a tumors Finally, the recent availability of markers of ovarian stroma, including Melan-A and inhibin-alpha, has provided a means for the positive identification of ovarian stromal tumors, which can manifest protean histological appearances. 11192073 Human
mart-1 melanoma MART-1 is a good candidate antigen for immunotherapy against HLA-A2 patients with melanoma, since it is a highly immunogenic antigen recognized by HLA-A2 and HLA-B45 restricted CD8+ cytotoxic T cells and expressed in the majority of melanoma lesions. 11154862 Human
mart-1 melanoma MART-1 was expressed in most melanocytic lesions, while HLA-A2 was down-regulated with melanoma disease progression. 11154862 Human
mart-1 melanoma Furthermore, concomitant down-regulation of MART-1 and HLA-A2 in melanoma cells was correlated with poor prognosis. 11154862 Human
mart-1 melanoma These findings suggest both MART-1 and HLA-A2 expression in melanoma lesions should be analyzed for selection of patients eligible for MART-1 based immunotherapy and monitoring for emergence of melanoma cells resistant to T cell therapy. 11154862 Human
melan-a tumor The percentages of positive cases of MMM (10% or more tumor cells positive) diagnosed with the four other markers in descending order were 90% (S100 protein and TYR), 78% (melan-A), and 66% (HMB45). 11176069 Human
melan-a tumors Focal Melan-A positivity was seen in 3 of 7 (43%) tumors. 11211309 Human
mart-1 stage iv melanoma Ex vivo ELISPOT analysis of peripheral blood lymphocytes obtained from stage IV melanoma patients demonstrated reactivity against peptides derived from MART-1 and gp100. 11212239 Human
melan-a ovarian neoplasms Melan-A (A103) and inhibin expression in ovarian neoplasms. 12966351 Human
mart1 primary cutaneous melanoma We looked for circulating cytotoxic T lymphocytes (CTL) directed against Melan-A / MART1, tyrosinase, gp100 and MAGE-3 antigens in patients with a diagnosis of primary cutaneous melanoma by using fluorescent HLA-A2 tetramers. 11180105 Human
melan-a primary cutaneous melanoma We looked for circulating cytotoxic T lymphocytes (CTL) directed against Melan-A / MART1, tyrosinase, gp100 and MAGE-3 antigens in patients with a diagnosis of primary cutaneous melanoma by using fluorescent HLA-A2 tetramers. 11180105 Human
mart-1 melanomas Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. 11169510 Human
mart-1 metastases Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. 11169510 Human
mart-1 melanoma With the recent availability of novel antibodies against melanoma antigens tyrosinase and MART-1, it is important to validate their usefulness in pathology practice and in screening patients for immunotherapy treatment. 11169510 Human
mart-1 cancer In the present study conducted by the Melanoma Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-MCG), immunohistochemical staining for gp100 (antibodies NKI-beteb and HMB-45), MART-1 (A103), tyrosinase (T311), and 11169510 Human
mart-1 malignant melanoma In the present study conducted by the Melanoma Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-MCG), immunohistochemical staining for gp100 (antibodies NKI-beteb and HMB-45), MART-1 (A103), tyrosinase (T311), and 11169510 Human
mart-1 melanoma In the present study conducted by the Melanoma Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-MCG), immunohistochemical staining for gp100 (antibodies NKI-beteb and HMB-45), MART-1 (A103), tyrosinase (T311), and 11169510 Human
mart-1 metastases In the present study conducted by the Melanoma Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-MCG), immunohistochemical staining for gp100 (antibodies NKI-beteb and HMB-45), MART-1 (A103), tyrosinase (T311), and 11169510 Human
mart-1 lymph-node metastases In the present study conducted by the Melanoma Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-MCG), immunohistochemical staining for gp100 (antibodies NKI-beteb and HMB-45), MART-1 (A103), tyrosinase (T311), and 11169510 Human
mart-1 tumour In the present study conducted by the Melanoma Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-MCG), immunohistochemical staining for gp100 (antibodies NKI-beteb and HMB-45), MART-1 (A103), tyrosinase (T311), and 11169510 Human
mart-1 melanoma The apparently stable expression of most of the melanoma antigens, and the small contribution of decreased expression in melanoma tumour progression, supports the rationale for immunotherapy based on the melanoma immunogens gp100, MART-1, and tyrosinase. 11169510 Human
mart-1 tumour The apparently stable expression of most of the melanoma antigens, and the small contribution of decreased expression in melanoma tumour progression, supports the rationale for immunotherapy based on the melanoma immunogens gp100, MART-1, and tyrosinase. 11169510 Human
mart-1 melanoma An immunoselected melanoma cell line that had lost expression of the dominant melanoma antigens MART-1 and gp100 was generated in an attempt to identify previously unknown tumor antigens. 11221837 Human
mart-1 tumor An immunoselected melanoma cell line that had lost expression of the dominant melanoma antigens MART-1 and gp100 was generated in an attempt to identify previously unknown tumor antigens. 11221837 Human
mart-1 melanoma One such Ag, MART-1, is expressed on >90% of human melanomas, and CTL generated against MART-1(27-35) kill most HLA A2.1(+) melanoma cells. 11207317 Human
mart-1 melanomas One such Ag, MART-1, is expressed on >90% of human melanomas, and CTL generated against MART-1(27-35) kill most HLA A2.1(+) melanoma cells. 11207317 Human
mart-1 tumor However, variant tumor cells, which do not express MART-1, down-regulate MHC, or become resistant to apoptosis, will escape killing. 11207317 Human
mart-1 tumor These findings demonstrate that drug-mediated sensitization can potentiate FasL-mediated killing by MHC-restricted CTL cell lines, independent of MHC and MART-1 expression on tumor cells. 11207317 Human
mart-1 tumor Tumor cells were positive for HMB 45, Melan-A (MART-1), and S-100 protein and negative for epithelial markers. 11263942 Human
melan-a tumor Tumor cells were positive for HMB 45, Melan-A (MART-1), and S-100 protein and negative for epithelial markers. 11263942 Human
melan-a melanoma HLA-A2+ melanoma patients develop naturally a strong CD8+ T cell response to a self-peptide derived from Melan-A. 11280765 Human
mart-1 melanoma Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein. 11297352 Human
mart-1 melanoma RT-PCR analysis for melanoma markers tyrosinase, gp100, MART-1, and MAGE-3 was performed, with Southern blot detection. 11368537 Human
melan a tumors Despite their epithelioid morphology, these tumors do not label immunohistochemically for epithelial markers but instead label focally for melanocytic markers HMB45 and Melan A. 11395386 Human
mart-1 melanoma RESULTS: All samples were positive for beta-actin and MART-1 and all but two were positive for tyrosinase, confirming RNA integrity and the presence of melanoma. 11397121 Human
mart-1 metastatic malignant melanoma Comparison of antibodies to MART-1 and MelanA in fine-needle aspiration samples of metastatic malignant melanoma. 11466819 Human
melan-a melanoma Priming of melan-A(26/27-35)-specific CTL occurs only in a fraction of late stage melanoma patients, whereas during the early stages of the disease and in healthy volunteers, melan-A CTL have functional and phenotypic markers consistent with a naive pheno 11466333 Human
mart-1 cancer We have investigated the possible usefulness of recombinant canarypox virus (ALVAC) encoding the melanoma-associated Ag, Melan-A/MART-1 (MART-1), in cancer immunotherapy, using a dendritic cell (DC)-based approach. 11466405 Human
melan a malignant tumors Three malignant tumors showed moderate to intense staining for Melan A/ MART-1. 11467477 Human
mart-1 malignant tumors Three malignant tumors showed moderate to intense staining for Melan A/ MART-1. 11467477 Human
mart-1 cutaneous melanoma Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45. 11474288 Human
melan-a cutaneous melanoma Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45. 11474288 Human
mart-1 melanoma We compared the new melanoma markers, Melan-A (clone A103) and MART-1 (clone M2-7C10), with S-100 protein and HMB-45, by examining 77 formalin-fixed paraffin-embedded sections of sentinel lymph nodes from 13 cases of primary cutaneous melanoma. 11474288 Human
melan-a melanoma We compared the new melanoma markers, Melan-A (clone A103) and MART-1 (clone M2-7C10), with S-100 protein and HMB-45, by examining 77 formalin-fixed paraffin-embedded sections of sentinel lymph nodes from 13 cases of primary cutaneous melanoma. 11474288 Human
mart-1 primary cutaneous melanoma We compared the new melanoma markers, Melan-A (clone A103) and MART-1 (clone M2-7C10), with S-100 protein and HMB-45, by examining 77 formalin-fixed paraffin-embedded sections of sentinel lymph nodes from 13 cases of primary cutaneous melanoma. 11474288 Human
melan-a primary cutaneous melanoma We compared the new melanoma markers, Melan-A (clone A103) and MART-1 (clone M2-7C10), with S-100 protein and HMB-45, by examining 77 formalin-fixed paraffin-embedded sections of sentinel lymph nodes from 13 cases of primary cutaneous melanoma. 11474288 Human
mart-1 melanoma Az values (area under receiver operating characteristic curve) with receiver operating characteristic curve were higher with Melan-A (0.9742) and MART-1 (0.9779) compared with S-100 protein (0.8034) and HMB-45 (0.8651), demonstrating a higher diagnostic a 11474288 Human
melan-a melanoma Az values (area under receiver operating characteristic curve) with receiver operating characteristic curve were higher with Melan-A (0.9742) and MART-1 (0.9779) compared with S-100 protein (0.8034) and HMB-45 (0.8651), demonstrating a higher diagnostic a 11474288 Human
mart-1 melanoma Melan-A and MART-1 showed sharp cytoplasmic immunoreactivity, almost exclusively restricted to the melanoma cells. 11474288 Human
melan-a melanoma Melan-A and MART-1 showed sharp cytoplasmic immunoreactivity, almost exclusively restricted to the melanoma cells. 11474288 Human
mart-1 cutaneous melanoma Therefore, Melan-A and MART-1 are recommended for the evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma as a routine alternative to S-100 protein and HMB-45. 11474288 Human
melan-a cutaneous melanoma Therefore, Melan-A and MART-1 are recommended for the evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma as a routine alternative to S-100 protein and HMB-45. 11474288 Human
melan a metastatic tumor However, initial follow-up surgical pathology reported only "extensive coagulative necrosis, no viable tumor seen." Subsequent immunohistochemical stains (cytokeratins (AE1/AE3), HMB45, S100, and Melan A) demonstrated the presence of metastatic 11477713 Human
melan a tumor However, initial follow-up surgical pathology reported only "extensive coagulative necrosis, no viable tumor seen." Subsequent immunohistochemical stains (cytokeratins (AE1/AE3), HMB45, S100, and Melan A) demonstrated the presence of metastatic 11477713 Human
melan a tumors Immunoreactivity of A103, an antibody to Melan A, in canine steroid-producing tissues and their tumors. 11478605 others
melan a tumors The monoclonal antibody A103 to the melanocytic differentiation antigen Melan A stains human steroid-producing cells and their tumors. 11478605 others
melan a tumors As in human tumors, immunohistochemistry for Melan A stains many canine steroid-producing tumors and can be used to distinguish these tumors from those of nonstereidogenic cells. 11478605 others
melan a human tumors As in human tumors, immunohistochemistry for Melan A stains many canine steroid-producing tumors and can be used to distinguish these tumors from those of nonstereidogenic cells. 11478605 Human
melan a melanoma Standard melanoma markers included S100, HMB45, HMB50, tyrosinase, and Melan A. Schwann cell markers included the p75 neurotrophin receptor (p75NTR), glial fibrillary acidic protein (GFAP), and the L1 adhesion protein. 11481518 Human
mart-1 recurrent nevi METHODS: We evaluated the original nevi (ON) and recurrent nevi (RN) of 15 patients by routine histology and immunohistochemistry (IHC), examining expression of S-100 protein, gp100 (with HMB-45), MART-1, tyrosinase, and the Ki-67 proliferation marker. 11493377 Human
mart-1 stage iv melanoma CSF was collected and assessed by RT-PCR for three known melanoma-associated markers (MAGE-3, MART-1, and tyrosinase) to detect occult metastatic melanoma cells in the CSF of 37 American Joint Committee on Cancer (AJCC) stage IV melanoma patients. 11511319 Human
mart-1 metastatic melanoma CSF was collected and assessed by RT-PCR for three known melanoma-associated markers (MAGE-3, MART-1, and tyrosinase) to detect occult metastatic melanoma cells in the CSF of 37 American Joint Committee on Cancer (AJCC) stage IV melanoma patients. 11511319 Human
mart-1 cancer CSF was collected and assessed by RT-PCR for three known melanoma-associated markers (MAGE-3, MART-1, and tyrosinase) to detect occult metastatic melanoma cells in the CSF of 37 American Joint Committee on Cancer (AJCC) stage IV melanoma patients. 11511319 Human
mart-1 metastases The correlation between CSF RT-PCR positivity of MART-1 and/or MAGE-3 and the development of CNS metastases at 3 mo was significant (p = 0.04). 11511319 Human
melan-a primary cutaneous melanoma METHODS: Thirty-five SLNs, 41 BM samples and 26 PB specimens from 26 patients with primary cutaneous melanoma (tumour thickness > or = 0.75 mm) were examined by nested RT-PCR for tyrosinase and Melan-A. 11531779 Human
melan-a tumour METHODS: Thirty-five SLNs, 41 BM samples and 26 PB specimens from 26 patients with primary cutaneous melanoma (tumour thickness > or = 0.75 mm) were examined by nested RT-PCR for tyrosinase and Melan-A. 11531779 Human
mart-1 melanoma RESULTS: Both cases exhibited melanoma in-situ, a conventional (non-chondroid) invasive component, and areas of chondroid differentiation, as confirmed by strongly positive staining with Alcian blue at pH 2.5 and Safranin O. Immunohistochemically, one cas 11553315 Human
melan-a melanoma Immunohistochemistry for specific markers of melanocytic differentiation such as HMB-45 and Melan-A can be very valuable in proving melanocytic differentiation in poorly differentiated or spindled forms of melanoma. 11556535 Human
melan a tumor One lesion expressed the tumor antigen (Melan A/ MART-1), but the other did not. 11556981 Human
mart-1 tumor One lesion expressed the tumor antigen (Melan A/ MART-1), but the other did not. 11556981 Human
mart-1 melanoma An autologous melanoma cell line selected for loss of expression of the immunodominant MART-1 and gp100 antigens was initially used to carry out a mixed lymphocyte tumor culture (MLTC) in a patient who expressed the human leukocyte antigen (HLA)-AI and HL 11565834 Human
mart-1 mixed lymphocyte tumor An autologous melanoma cell line selected for loss of expression of the immunodominant MART-1 and gp100 antigens was initially used to carry out a mixed lymphocyte tumor culture (MLTC) in a patient who expressed the human leukocyte antigen (HLA)-AI and HL 11565834 Human
melan-a ovarian cystic teratoma The tumor showed immunoreactivity for Melan-A, S-100 and HMB-45 in the absence of melanin granules, which established the diagnosis of amelanotic malignant melanoma arising in an ovarian cystic teratoma. 11575655 Human
melan-a amelanotic malignant melanoma The tumor showed immunoreactivity for Melan-A, S-100 and HMB-45 in the absence of melanin granules, which established the diagnosis of amelanotic malignant melanoma arising in an ovarian cystic teratoma. 11575655 Human
melan-a tumor The tumor showed immunoreactivity for Melan-A, S-100 and HMB-45 in the absence of melanin granules, which established the diagnosis of amelanotic malignant melanoma arising in an ovarian cystic teratoma. 11575655 Human
mart1 melanoma Similarly, the melanocytic markers MLANA/MART1 and MITF also have been shown to lose relative expression during melanoma progression. 14744763 Human
mlana melanoma Similarly, the melanocytic markers MLANA/MART1 and MITF also have been shown to lose relative expression during melanoma progression. 14744763 Human
melan-a tumours The Melan-A antibody labelled all balloon cell tumours and one signet-ring cell tumour, whereas the anti-tyrosinase antibody was not reactive in any of the tumours. 11578133 others
melan-a tumour The Melan-A antibody labelled all balloon cell tumours and one signet-ring cell tumour, whereas the anti-tyrosinase antibody was not reactive in any of the tumours. 11578133 others
melan-a tumours The Melan-A antibody also labelled a variety of canine epithelioid and spindle cell melanomas; non-melanocytic tumours were all negative. 11578133 others
melan-a spindle-cell melanomas The Melan-A antibody also labelled a variety of canine epithelioid and spindle cell melanomas; non-melanocytic tumours were all negative. 11578133 others
melan-a canine melanomas Melan-A antibody was found to be useful in the diagnosis of pigmented and non-pigmented canine melanomas. 11578133 others
melan-a tumor The resulting CTL efficiently lysed tumor cells expressing Melan-A Ag. 11698460 Human
melan a melanoma CONCLUSION: The prognostic value of this method could be improved by combining it with PCR of other melanoma markers (Melan A, Mage 3) or assays of serum markers (S 100 protein or lactate dehydrogenase). 11701975 Human
melan-a tumor The peptide derived from the melanoma-associated protein Melan-A (Melan-A(26-35)/HLA-A2) is an attractive candidate for tumor immunotherapy but little is known about the intracellular processing of this antigen. 11551907 Human
melan-a melanoma In transfected melanoma cells, Melan-A accumulates in the Golgi region. 11551907 Human
melan-a melanoma Most strikingly, melanoma cells expressing this form of Melan-A are more effectively recognized by specific CTL than those expressing either Melan-A in its native membrane orientation or Melan-A artificially localized in the cytosol. 11551907 Human
mart-1 malignant melanoma of the skin But immunohistological staining showed positivity for S-100 and MART-1, as did the primary tumour. - CONCLUSIONS: If atypical bleeding in patients with known malignant melanoma of the skin occur endometrial metastasis should be excluded by gynaecologists. 11709747 Human
mart-1 metastasis But immunohistological staining showed positivity for S-100 and MART-1, as did the primary tumour. - CONCLUSIONS: If atypical bleeding in patients with known malignant melanoma of the skin occur endometrial metastasis should be excluded by gynaecologists. 11709747 Human
mart-1 primary tumour But immunohistological staining showed positivity for S-100 and MART-1, as did the primary tumour. - CONCLUSIONS: If atypical bleeding in patients with known malignant melanoma of the skin occur endometrial metastasis should be excluded by gynaecologists. 11709747 Human
melan a iris melanoma Immunohistochemical studies showed that the iris melanocytes were negative for HMB45 and S-100, and weakly positive for Melan A. CONCLUSION: Latanoprost-associated iris color change may exhibit a diffuse, uniform, dark velvet-brown appearance, thereby sim 11711840 Human
mart-1 melanoma Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. 11759068 Human
mart-1 metastases Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. 11759068 Human
mart-1 tumor The tumor cells were negative for HMB-45 and MART-1. 11737519 Human
mart-1 melanomas Metastatic tumours from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 tumour-loss variants (median 0% MART-1-positive tumour) compared to matched metastatic tumours from patients 11745443 Human
mart-1 primary tumours Metastatic tumours from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 tumour-loss variants (median 0% MART-1-positive tumour) compared to matched metastatic tumours from patients 11745443 Human
mart-1 occult primary melanoma Metastatic tumours from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 tumour-loss variants (median 0% MART-1-positive tumour) compared to matched metastatic tumours from patients 11745443 Human
mart-1 tumour Metastatic tumours from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 tumour-loss variants (median 0% MART-1-positive tumour) compared to matched metastatic tumours from patients 11745443 Human
mart-1 tumour A correlation with the presence of peripheral blood MART-1-specific CTLs (MHC class I-restricted IFN-gamma producing T lymphocytes) and MART-1 tumour antigen-loss variants was found (p = 0.001). 11745443 Human
mart-1 stage iv melanoma Two HLA-A2-positive patients with advanced stage IV melanoma were treated with monocyte-derived dendritic cells (DC) pulsed with either tumor peptide antigens from gp100, MART-1 and MAGE-3 alone or in combination with autologous oncolysates. 11745484 Human
mart-1 tumor Two HLA-A2-positive patients with advanced stage IV melanoma were treated with monocyte-derived dendritic cells (DC) pulsed with either tumor peptide antigens from gp100, MART-1 and MAGE-3 alone or in combination with autologous oncolysates. 11745484 Human
mart-1 metastatic malignant melanoma (mmm) BACKGROUND: MART-1 and gp100 currently are utilized as targets in immunotherapy protocols for metastatic malignant melanoma (MMM). 11748581 Human
mart-1 melanoma We wanted to determine the role of CD4 cells and CD40 ligation of MART-1 gene-modified DC in an animal model of immunotherapy for murine melanoma. 11751400 Human
melan-a adenoma However, only the adenoma was sporadic melan-A positive. 11782230 Human
melan-a adenoma Of the presented cases only the RPE adenoma is sporadic melan-A positive. 11782230 Human
melan-a pigmented spindle cell nevi Expression of Melan-A in Spitz, pigmented spindle cell nevi, and congenital nevi: comparative immunohistochemical study. 10644168 Human
melan-a pigmented spindle cell nevi The expression of the antibody Melan-A in 27 benign melanocytic skin lesions (10 congenital nevi, 10 Spitz nevi, and 7 pigmented spindle cell nevi) was compared to that of S100 protein and HMB-45. 10644168 Human
melan-a granular-cell tumors To evaluate the role of Melan-A in differentiating melanocytic and nonmelanocytic lesions we assessed a number of benign nonmelanocytic skin lesions including neurofibromas, granular cell tumors, and dermatofibromas. 10644168 Human
melan-a tumor To further define the role of MGSA/GRO proteins in melanocyte transformation, two types of experiments were designed to neutralize the biological effects of MGSA/GRO in the transfected melan-a clones: (1) the effect of neutralizing antiserum to MGSA/GRO p 10647998 Human
melan-a tumor These experiments revealed that SCID mice inoculated with MGSA/GROalpha- or gamma-expressing melan-a cells and subsequently treated with antiserum to the respective chemokine exhibited decreased tumor growth. 10647998 Mouse
melan-a melanoma Originally studied as a melanoma marker, Melan-A, as detected by the murine monoclonal antibody, A103, has gained recent attention as a marker for steroid-producing cells. 10664633 Human
mart-1 metastatic melanoma HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. 14991540 Human
mart-1 metastases to lymph nodes We examined the staining patterns of S-100, NK1/C3, HMB-45, and MART-1 (DC10) in melanoma metastases to lymph nodes. 14991540 NA
mart-1 melanoma We examined the staining patterns of S-100, NK1/C3, HMB-45, and MART-1 (DC10) in melanoma metastases to lymph nodes. 14991540 NA
melan-a melanoma Forty-nine HLA-A2 positive patients with Melan-A positive melanoma were repeatedly vaccinated with Melan-A peptide, with or without immune adjuvant AS02B (QS21 and MPL) or IFA. 15149168 Human
melan a melanoma In addition, a clinical study with autologous dendritic cells pulsed with synthetic melanoma peptides derived from the MART1/ Melan A, gp100, and tyrosinase proteins was conducted. 10685662 Human
mart1 melanoma In addition, a clinical study with autologous dendritic cells pulsed with synthetic melanoma peptides derived from the MART1/ Melan A, gp100, and tyrosinase proteins was conducted. 10685662 Human
mart-1 metastatic melanoma Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression. 10687135 Human
mart-1 tumor infiltrating lymphocytes Tumor infiltrating lymphocytes from a patient with melanoma were isolated, expanded in vitro in the presence of interleukin-2, and tested for cytotoxicity against HLA-A2 positive, MART-1 positive autologous tumor cells, an HLA-A2-positive, MART-1 positive 10687135 Human
mart-1 melanoma Tumor infiltrating lymphocytes from a patient with melanoma were isolated, expanded in vitro in the presence of interleukin-2, and tested for cytotoxicity against HLA-A2 positive, MART-1 positive autologous tumor cells, an HLA-A2-positive, MART-1 positive 10687135 Human
mart-1 autologous tumor Tumor infiltrating lymphocytes from a patient with melanoma were isolated, expanded in vitro in the presence of interleukin-2, and tested for cytotoxicity against HLA-A2 positive, MART-1 positive autologous tumor cells, an HLA-A2-positive, MART-1 positive 10687135 Human
mart-1 autologous tumor These CTL preferentially recognized the MART-1 peptide F119, 27-35, and gp100 peptide F125, 280-288, resulting in a 30% to 60% enhancement of lysis when autologous tumor or major histocompatibility complex class I "empty" T2 cells were pulsed wi 10687135 Human
mart-1 melanoma The murine melanoma B16 expresses the murine counterpart of the human MART-1/Melan-A (MART-1) antigen, sharing a 68.6% amino acid sequence identity. 10687138 Mouse
mart-1 b16 melanoma In conclusion, dendritic cells genetically modified to express the human MART-1 antigen generate potent murine MART-1-specific protective responses to B16 melanoma. 10687138 Mouse
mart-1 melanoma Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma. 10687150 Human
mart-1 melanocytic nevi A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. 10688724 Human
mart-1 malignant melanomas A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. 10688724 Human
mart-1 melanocytic nevi OBJECTIVE: We attempted to elucidate the pattern of expression of a newly recognized melanocyte-specific melanosomal protein MART-1 in routinely processed specimens of SNs, MMs, and ordinary melanocytic nevi (MNs) and to see whether it can help to differe 10688724 NA
mart-1 tumor RESULTS: All SNs, MNs, and MMs demonstrated cytoplasmic staining for MART-1 in some of their tumor cells, of which 17 of 20 (85%) and 24 of 27 (89%) of SN and MN, respectively, demonstrated positive stainings in more than half of their tumor cells, as com 10688724 Human
mart-1 tumors CONCLUSION: MART-1 does not differentiate between SN, MM, and ordinary MN in a consistent pattern, but it may be used as a marker for these tumors. 10688724 Human
mart-1 cancer Replication-deficient recombinant adenovirus (Ad) encoding human gp100 or MART-1 melanoma Ag was used to transduce human dendritic cells (DC) ex vivo as a model system for cancer vaccine therapy. 10706736 Human
melan-a tumors The tumors had immunoreactivity for S-100 protein (11 of 11), HMB-45 ( 10 of 11), Melan-A (four of four), tyrosinase (four of four), and CD34 (four of four). 10716146 Human
mart-1 melanoma Melanoma-reactive HLA-A x 0201-restricted cytotoxic T lymphocyte (CTL) lines generated in vitro lyse autologous and HLA-matched allogeneic melanoma cells and recognize multiple shared peptide antigens from tyrosinase, MART-1, and Pme117/gp100. 10752474 Human
mart-1 tumor The correct diagnosis was made with an immunohistochemical panel revealing tumor cell positivity for CD68 and negativity for S-100 protein and MART-1. 10770441 Human
melan-a melanoma We then describe a relatively simple and efficient procedure that allowed us to obtain systematically high amounts (in the range of billion) of high avidity Melan-A/ MART-1-specific T cells from the PBLs of HLA-A2 melanoma patients and healthy donors in 3 10778978 Human
melan-a melanomas Typically melanomas are S100 protein, NKIC3, HMB-45, Melan-A and tyrosinase positive but some melanomas may exhibit an aberrant immunophenotype and may express cytokeratins, desmin, smooth muscle actin, KP1 (CD68), CEA, EMA and VS38. 10792480 Human
melan-a tumor Immunohistochemical analysis showed vimentin, S-100 protein, Melan-A, and HMB-45 immunoreactivity in most of the tumor cells. 10800995 Human
mart-1 melanoma Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA iso 10803712 Human
mart-1 stage iv melanoma In addition, RNA was extracted from paired blood samples from 24 analysable stage III and stage IV melanoma patients and analysed for the presence of tyrosinase and MART-1 RNA using both the CPT/RNeasy and the whole blood/GITC method. 10803712 Human
melan-a melanoma Additional antigen-independent expansion with anti-CD3/anti-CD28 monoclonal antibodies together with interleukin-2 gave rise to 600-fold expansion of CD8+ CTLs that maintained Melan-A specificity and were able to efficiently lyse Melan-A-expressing melano 10815925 Human
melan-a tumours Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. 10823140 Human
melan-a tumours AIMS: To assess A103 (melan-A) immunoreactivity in a range of ovarian sex cord stromal tumours and to evaluate it for the differential diagnosis of other neoplasms. 10823140 NA
melan-a neoplasms AIMS: To assess A103 (melan-A) immunoreactivity in a range of ovarian sex cord stromal tumours and to evaluate it for the differential diagnosis of other neoplasms. 10823140 NA
mart-1 melanoma MART-1, a melanoma antigen recognized by T cells-1, is a melanocyte lineage-differentiation antigen expressed only in melanocytes and melanoma cells. 10838667 Human
mart-1 melanoma In preparation for a phase I clinical trial of MART-1 polynucleotide immunization in patients with resected melanoma who were at significant risk for recurrence, the authors constructed a plasmid DNA encoding the MART-1 cDNA under transcriptional regulato 10838667 Human
melan-a tumors All tumors were completely negative for tyrosinase (T311), gp100 (HMB-45), and Melan-A (A103). 10843290 Human
mart-1 cancer In this study, we measured the absolute levels of MA messenger ribonucleic acid (mRNA) in tumor cell lines utilizing real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). mRNA levels of MART-1, gp100, tyrosinase, TRP-1 and TRP- 10842196 Human
mart-1 melanoma In this study, we measured the absolute levels of MA messenger ribonucleic acid (mRNA) in tumor cell lines utilizing real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). mRNA levels of MART-1, gp100, tyrosinase, TRP-1 and TRP- 10842196 Human
melan-a melanocytic nevi To explore the use of immunohistochemistry for this diagnostic problem, we examined the expression of S-100 protein, gp100 (the antigen recognized by HMB-45), tyrosinase (T311), Melan-A (A103), Factor XIIIa (FXIIIa), and CD68 in 10 juvenile xanthogranulom 10871066 Human
melan-a melanocytic nevi All epithelioid melanocytic nevi were immunoreactive for Melan-A, tyrosinase, and S-100 protein in most melanocytes. 10871066 Human
melan-a tumors Our results demonstrate that Melan-A and tyrosinase are sensitive and specific markers to distinguish epithelioid melanocytic nevi from epithelioid histiocytic tumors. 10871066 Human
melan-a melanocytic nevi Our results demonstrate that Melan-A and tyrosinase are sensitive and specific markers to distinguish epithelioid melanocytic nevi from epithelioid histiocytic tumors. 10871066 Human
mart-1 malignant melanoma We stained benign melanocytic nevi and malignant melanoma with antibodies to melanoma antigen recognized by T cells (Mart-1) to determine if this was useful in differentiating benign from malignant melanocytic neoplasms. 10871068 Human
mart-1 melanocytic neoplasms We stained benign melanocytic nevi and malignant melanoma with antibodies to melanoma antigen recognized by T cells (Mart-1) to determine if this was useful in differentiating benign from malignant melanocytic neoplasms. 10871068 Human
mart-1 benign melanocytic nevi We stained benign melanocytic nevi and malignant melanoma with antibodies to melanoma antigen recognized by T cells (Mart-1) to determine if this was useful in differentiating benign from malignant melanocytic neoplasms. 10871068 Human
mart-1 primary malignant melanomas Forty-five primary malignant melanomas and 71 benign melanocytic nevi were stained with antibodies to Mart-1. 10871068 Human
mart-1 benign melanocytic nevi Forty-five primary malignant melanomas and 71 benign melanocytic nevi were stained with antibodies to Mart-1. 10871068 Human
mart-1 primary malignant melanomas Thirty-six of 45 primary malignant melanomas stained diffusely positive with antibodies to Mart-1. 10871068 Human
mart-1 melanocytic nevi Sixty-one of 71 melanocytic nevi showed no staining or faint staining with antibodies to Mart-1. 10871068 Human
mart-1 malignant melanoma Staining with antibodies to Mart-1 antigen was a useful marker of malignant melanoma. 10871068 Human
mart-1 tumors The presence or absence of staining for Mart-1 antigen cannot be used to differentiate benign melanocytic nevi from malignant melanocytic tumors. 10871068 Human
mart-1 benign melanocytic nevi The presence or absence of staining for Mart-1 antigen cannot be used to differentiate benign melanocytic nevi from malignant melanocytic tumors. 10871068 Human
mart-1 metastatic melanoma Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 10916759 Human
mart-1 malignant melanoma Melanoma antigen recognized by T cell 1 (MART-1) is regarded as a candidate peptide for vaccination against malignant melanoma, and it is of importance to develop strategies to improve the vaccine-elicited T-cell activation towards MART-1. 14871300 Human
melan-a tumor We recommend that (1) biopsies be stained preoperatively for Melan-A and/or HMB-45, (2) a debulking layer be obtained for permanent sections prior to Mohs layers, and positive and negative control specimens from the tumor and distant skin should be employ 10940065 Human
melan-a tumors In three of the seven cases studied immunohistochemically, the tumors expressed smooth muscle actin, melan-A, microphthalmia transcription factor (MiTF), and myosin, but not desmin. 10976698 Human
melan-a tumor Immunohistochemical stains for smooth muscle actin, Melan-A, and HMB-45 were positive in most of the tumor cells. 10976706 Human
melan-a malignant melanoma of the conjunctiva Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. 10985669 Human
mart-1 melanoma These include melanocyte specific proteins, such as tyrosinase, TRP1, TRP2, gp100, and MART-1, cancer-testis antigens, and mutated peptides derived from genetic alterations in melanoma cells. 11041376 Human
melan a amelanotic melanomas Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. 14608029 Human
melan a tumors To determine whether TRP-2 would be a good diagnostic marker for amelanotic melanomas of the dog, we performed immunohistochemistry for TRP-2, S-100, and Melan A on 21 canine tumors identified as amelanotic melanomas based on routine histopathologic exami 14608029 Human
melan a amelanotic melanomas To determine whether TRP-2 would be a good diagnostic marker for amelanotic melanomas of the dog, we performed immunohistochemistry for TRP-2, S-100, and Melan A on 21 canine tumors identified as amelanotic melanomas based on routine histopathologic exami 14608029 Human
melan a tumors Thirteen of the tumors were TRP-2 positive, 10 were Melan A positive, and 19 were S-100 positive. 14608029 others
melan a tumors Neither Melan A nor TRP-2 antibodies reacted with these tumors. 14608029 others
melan-a melanoma In particular, the HLA-B35-restricted Melan-A epitope is mimicked by the peptide 26-35, already known as the most immunodominant melanoma epitope in the HLA-A*0201 context. 14634146 Human
melan-a melanoma We used phenotypic markers to characterize melan-A tetramer(+) cells in both normal individuals and melanoma patients, and correlated these markers with ex vivo assays of CTL function. 11086110 Human
melan-a melanoma Melanoma patients with detectable melan-A tetramer(+) cells in peripheral blood fell into two groups. 11086110 Human
melan-a malignant melanoma Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. 11095072 Human
melan a metastatic melanomas Immunohistochemically, Melan A was detected in 113/122 oral (92.6%) and 5/7 (71.9%) metastatic melanomas. 11105949 others
melan a tumors Only 4/163 nonmelanocytic tumors were focally and weakly positive for Melan A. 11105949 others
melan a canine melanomas We conclude that Melan A is a specific and sensitive marker for canine melanomas. 11105949 others
mart-1 melanoma Quantification of melanoma cell-specific MART-1 mRNA in peripheral blood by a calibrated competitive reverse transcription-PCR. 11106324 Human
mart-1 melanoma METHODS: To establish a calibration curve, we measured the concentration of MART-1 mRNA in SK-MEL-28 melanoma cells grown in vitro by competitive RT-PCR. 11106324 NA
mart-1 melanoma RESULTS: Addition of melanoma cells grown in vitro to blood from healthy donors demonstrated that the method can detect a single SK-MEL-28 melanoma cell in 1 mL of blood (1.5 x 10(-21) mol MART-1 mRNA/mL). 11106324 Human
mart-1 malignant melanoma MART-1 mRNA was observed in 4 of 12 blood samples from patients with malignant melanoma, at concentrations of 3-18 x 10(-21) mol MART-1 mRNA/mL of blood. 11106324 Human
mart-1 malignant melanoma No MART-1 mRNA was detected in blood samples from 25 controls without malignant melanoma. 11106324 Human
mart-1 melanoma In this study, we show that human DCs derived from monocytes and loaded with killed melanoma cells prime naive CD45RA(+)CD27(+)CD8(+) T cells against the four shared melanoma antigens: MAGE-3, gp100, tyrosinase, and MART-1. 11104796 Human
mart-1 melanoma Current strategies for the immunotherapy of melanoma include augmentation of the immune response to tumor antigens represented by melanosomal proteins such as tyrosinase, gp100, and MART-1. 11104805 Human
mart-1 tumor Current strategies for the immunotherapy of melanoma include augmentation of the immune response to tumor antigens represented by melanosomal proteins such as tyrosinase, gp100, and MART-1. 11104805 Human
mart-1 metastatic tumors Neoplastic cells of both primary and metastatic tumors immunostained positively for S-100, HMB45, MART-1, and vimentin antibodies, but they were negative for cytokeratins 1-19, 8, 18, and 8,18; <10% of neoplastic cells in both the primary and the metastat 11127926 Human
mart-1 metastatic melanomas Neoplastic cells of both primary and metastatic tumors immunostained positively for S-100, HMB45, MART-1, and vimentin antibodies, but they were negative for cytokeratins 1-19, 8, 18, and 8,18; <10% of neoplastic cells in both the primary and the metastat 11127926 Human
melan a epithelioid angiosarcoma The unusual morphology of the tumor demanded special immunohistochemical investigation (factor 8, CD 31, CD 34, pancytokeratin 20, LCA, S100, cytokeratin 7, CEA, MU1, HMB 45 and melan A) which confirmed the diagnosis of epithelioid angiosarcoma. 11198045 Human
melan a tumor The unusual morphology of the tumor demanded special immunohistochemical investigation (factor 8, CD 31, CD 34, pancytokeratin 20, LCA, S100, cytokeratin 7, CEA, MU1, HMB 45 and melan A) which confirmed the diagnosis of epithelioid angiosarcoma. 11198045 Human
mart-1 tumor In addition, some of the markers may identify patients likely to respond better to a new type of therapy (e.g., anti-angiogenic therapy in a patient whose tumor is overexpressing VEGF or immunotherapy for a patient whose tumor is expressing high levels of 11221516 Human
mart-1 melanoma Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. 10537339 Human
mart-1 melanoma Twenty-five patients with high-risk resected stages IIB, III, and IV melanoma were immunized with a vaccine consisting of the minimal epitope, immunodominant 9-amino acid peptide derived from the MART-1 tumor antigen (AAGIGILTV) complexed with incomplete 10537339 Human
mart-1 tumor Twenty-five patients with high-risk resected stages IIB, III, and IV melanoma were immunized with a vaccine consisting of the minimal epitope, immunodominant 9-amino acid peptide derived from the MART-1 tumor antigen (AAGIGILTV) complexed with incomplete 10537339 Human
mart-1 melanoma MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. 10561323 Human
mart-1 metastases MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. 10561323 Human
mart-1 melanoma PURPOSE: Polymerase chain reaction (PCR) with tyrosinase and with MART-1 permits detection of small numbers of circulating melanoma cells (CMCs) in patients who have undergone surgical resection of localized disease. 10561323 NA
mart-1 cancer PATIENTS AND METHODS: We analyzed the prognostic significance of the patterns of expression of tyrosinase and MART-1 in 186 patients followed sequentially before and after surgical removal of American Joint Committee on Cancer stage I, II, or III melanoma 10561323 NA
mart-1 melanoma PATIENTS AND METHODS: We analyzed the prognostic significance of the patterns of expression of tyrosinase and MART-1 in 186 patients followed sequentially before and after surgical removal of American Joint Committee on Cancer stage I, II, or III melanoma 10561323 NA
mart-1 metastases Patients with locoregional metastases had CMCs that expressed tyrosinase and MART-1 at similar rates. 10561323 Human
mart-1 metastases CONCLUSION: These findings suggest that PCR with MART-1 and with tyrosinase identifies subgroups of patients who develop disseminated or locally recurrent metastases. 10561323 Human
mart-1 metastases We hypothesize that immune responses against MART-1 may reduce the establishment of disseminated metastases. 10561323 Human
mart-1 melanoma Nineteen patients received DCs plus autologous lysates and 14 patients DCs plus peptides from the melanoma antigens MAGE-3.A2, tyrosinase, gp100, and MART-1. 14600790 Human
mart-1 melanoma Approximately half the patients had responses to MART-1 peptide and a third to the other melanoma peptides. 14600790 Human
mart-1 mouse fibrosarcoma The MART-1 gene was stably transfected into the nonimmunogenic mouse fibrosarcoma cell line NFSA that is syngeneic in C3Hf/Sem/Kam (C3H, H-2k) mice to generate the NFSA(MART1) cell line. 10608349 Human
mart-1 tumor In vivo protection from a lethal NFSA(MART1) tumor challenge could be generated by DCs transduced with a recombinant adenovirus (AdV) vector expressing MART-1 (AdVMART1). 10608349 Human
mart-1 melanoma The melanoma proteins, MART-1 and gp100, were used to induce potentially tumor-reactive T cells, and the intensity of T cell staining by TCR binding of specific peptide-MHC tetramers was assessed. 9973498 Human
melan-a cancer Our results indicate that the HLA-A*0201/Kb transgenic mouse is a useful animal model to perform preclinical testing of potential cancer vaccines, and that Melan-A peptide analogues are attractive candidates for melanoma immunotherapy. 10092815 Mouse
melan-a melanoma Our results indicate that the HLA-A*0201/Kb transgenic mouse is a useful animal model to perform preclinical testing of potential cancer vaccines, and that Melan-A peptide analogues are attractive candidates for melanoma immunotherapy. 10092815 Mouse
mart-1 metastatic malignant melanoma Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. 10096358 Human
mart-1 neoplasms To test the specificity of the monoclonal antibody directed against MART-1, the authors evaluated its reactivity in normal tissues as well as in various nonpigmented neoplasms that are often included in the differential diagnosis of MM. 10096358 Human
melan-a melanoma In the present study, we have derived polyclonal monospecific cell lines from circulating Melan-A-specific CTL precursors of HLA-A*0201+ melanoma patients by combining stimulation with recently identified peptide analogues of the immunodominant epitope fr 10232604 Human
mart-1 melanoma The new melanoma markers: MART-1 and Melan-A (the NIH experience) 10328095 Human
melan-a melanoma The new melanoma markers: MART-1 and Melan-A (the NIH experience) 10328095 Human
melan a melanoma Using single- and double-labelling immunohistochemistry, cultured cells and paraffin sections were analysed for a range of melanoma (HMB45, Melan A, S100 and tyrosinase) and immune cell (CD68, CD163, CD45 and CD1a) markers. 15113392 Human
melan-a metastatic melanoma METHODS: Ninety-nine positive SLNs from 72 patients were retrospectively reviewed for the presence of microscopic metastatic melanoma on hematoxylin and eosin (H&E), S-100, HMB-45, and Melan-A stained sections and sensitivities of each immunohistochemical 15097961 NA
melan-a metastatic melanoma If the H&E sections are negative or equivocal for metastatic melanoma, immunohistochemistry staining with S-100 protein and Melan-A is performed. 15097961 Human
mart1 melanoma MART1 and MelanA are considered sensitive markers of melanocytic differentiation and are used to increase the detection of melanoma micrometastases in sentinel lymph nodes (SLNs). 15105646 Human
mart-1 melanoma RESULTS: When used with antibody directed against MART-1 for frozen section evaluation of melanoma, the section staining is reproducible and specific for melanocytes. 15008870 Human
melan-a melanomas Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. 11756773 Human
melan-a melanoma In this study the immunostaining profile of HMB45-negative malignant melanomas was evaluated by a panel of antibodies against markers associated with melanoma and melanocytic differentiation, including microphthalmia transcription factor, tyrosinase, Mela 11756773 NA
melan-a malignant melanomas In this study the immunostaining profile of HMB45-negative malignant melanomas was evaluated by a panel of antibodies against markers associated with melanoma and melanocytic differentiation, including microphthalmia transcription factor, tyrosinase, Mela 11756773 NA
melan-a malignant melanomas Of eight HMB45-positive malignant melanomas, all were positive for Melan-A, tyrosinase, and melanocyte-specific transcription factor, and three were positive for MAGE-1. 11756773 Human
melan-a melanomas In the 14 HMB-45 negative, nondesmoplastic melanomas, melanocyte-specific transcription factor was positive in 9, Melan-A in 9, tyrosinase in 6, and MAGE-1 in 11. 11756773 Human
mart-1 lentigo maligna Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. 11756950 Human
melan-a sinonasal melanomas Melan-A as a useful diagnostic immunohistochemical stain for the diagnosis of primary sinonasal melanomas. 11774402 Human
melan-a sinonasal melanoma METHODS: Seven cases of sinonasal melanoma were assessed for reactivity with Melan-A, S-100 protein and HMB-45. 11774402 NA
melan-a sinonasal melanomas CONCLUSION: Because Melan-A can be positive in cases that are S-100 protein or HMB-45 negative, it is a useful component in the immunohistochemical panel for the diagnosis of sinonasal melanomas. 11774402 Human
mart-1 melanoma We have performed a detailed analysis of the recognition of melanoma Ags by the tumor-infiltrating lymphocytes (TIL) 1790, isolated from a patient who experienced a dramatic tumor regression following immunization with peptides from the gp100, MART-1, and 11777994 Human
mart-1 tumor We have performed a detailed analysis of the recognition of melanoma Ags by the tumor-infiltrating lymphocytes (TIL) 1790, isolated from a patient who experienced a dramatic tumor regression following immunization with peptides from the gp100, MART-1, and 11777994 Human
melan-a renal tumors OBJECTIVES: To evaluate expression of the novel melanocytic markers mitf and tyrosinase in angiomyolipomas, and to compare these markers with the established markers HMB-45 and melan-A in both hepatic and renal tumors. 11800647 NA
melan-a angiomyolipoma The extent and intensity of immunostaining with HMB-45 and melan-A were dependent on whether spindled or epithelioid cells predominated; the epithelioid cells showed stronger and more widespread reactivity than the spindled cells.CONCLUSION: We believe th 11800647 Human
mart-1 neurilemmoma Diffuse Mart-1 positivity excluded a collision of a melanocytic lesion with a neurilemmoma. 11803280 Human
mart-1 melanoma Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. 10360670 Human
mart-1 melanoma We present a quality control study in which we analysed the reproducibility of detection of tyrosinase and MART-1 transcripts in 106 blood samples from 68 melanoma patients (mainly stages III and IV). 10360670 Human
mart-1 melanoma When applying real-time quantitative PCR for tyrosinase and MART-1, we found that a low amount of SK-MEL-28 cell equivalents was present in the blood of melanoma patients, with a higher number of equivalents in the group with a consistently positive resul 10360670 Human
mart-1 metastatic melanoma We identified circulating CD8+ T-cell populations specific for the tumor-associated antigens (TAAs) MART-1 (27-35) or tyrosinase (368-376) in six of eleven patients with metastatic melanoma using peptide/HLA-A*0201 tetramers. 10371507 Human
melan-a tumours AIMS: The purpose of this study was to test different malignant non-melanocytic tumours with the commercially available antibody Melan-A to examine its diagnostic specificity and to compare the S100, Melan-A and HMB-45 reactivity in various melanocytic le 10383696 NA
melan-a malignant melanomas The epithelioid and the spindle cells in malignant melanomas did not show considerable difference in their Melan-A reactivity. 10383696 Human
melan-a desmoplastic melanomas In desmoplastic melanomas the positivity of Melan-A was not consistent. 10383696 Human
melan-a sarcomas None of the sarcomas, carcinomas and carcinoids expressed Melan-A. 10383696 Human
melan-a carcinomas None of the sarcomas, carcinomas and carcinoids expressed Melan-A. 10383696 Human
melan-a metastatic melanoma CONCLUSIONS: Melan-A is a useful additional marker to differentiate non-melanocytic tumours from primary or metastatic melanoma. 10383696 Human
melan-a tumours CONCLUSIONS: Melan-A is a useful additional marker to differentiate non-melanocytic tumours from primary or metastatic melanoma. 10383696 Human
melan-a desmoplastic melanomas In desmoplastic melanomas, however, the variable Melan-A staining further necessitated detailed histological examination and the use of the S100 reaction. 10383696 Human
mart-1 melanomas The tumor-associated-Ag MART-1 is expressed by most human melanomas. 10384155 Human
mart-1 melanoma These retrovirally transduced PBL cultures were MART-1 peptide reactive, and most cultures recognized HLA-A2+ melanoma lines. 10384155 Human
melan-a angiomyolipoma We also performed RT-PCR assays for gp-100 and Melan-A in 4 of the 18 angiomyolipoma samples and in three normal kidney samples. 10389626 Human
mart-1 tumor In addition, some of the markers may identify patients likely to respond better to a new type of therapy (e.g., anti-angiogenic therapy in a patient whose tumor is overexpressing VEGF or immunotherapy for a patient whose tumor is expressing high levels of 10410863 Human
mart-1 cancer Especially where these peptides may be used in human clinical trials for the treatment or prevention of cancer, there is substantial need for direct evaluation of HLA-A*0201-associated peptides from MART-1 and gp100 that are naturally processed and presen 10417764 Human
mart-1 metastases RESULTS: Deeper sections into the lymph node and immunohistochemical stains with antibodies to S-100, HMB-45, NK1C3, and MART-1 led to the identification of microscopic metastases in 11 sentinel lymph nodes from 11 patients and capsular nevi in 9 sentinel 10440689 Human
melan-a melanoma Immunohistochemistry and sentinel node biopsy in melanoma: the use of tyrosinase and Melan-A. 10468824 Human
melan-a melanoma Using fluorescent HLA-A*0201 tetramers containing the immunodominant Melan-A/MART-1 (Melan-A) tumor-associated antigen (Ag), we previously observed that metastatic lymph nodes of melanoma patients contain high numbers of Ag-experienced Melan-A-specific cy 10477554 Human
mart-1 metastases Their SNs were serially sectioned and assessed for MAGE-3, MART-1, and tyrosinase mRNA expression by RT-PCR, in parallel with H&E staining and IHC, for melanoma metastases. 10506625 Human
mart-1 melanoma Their SNs were serially sectioned and assessed for MAGE-3, MART-1, and tyrosinase mRNA expression by RT-PCR, in parallel with H&E staining and IHC, for melanoma metastases. 10506625 Human
melan a angiomyolipoma Angiomyolipoma was excluded by negative staining for HMB45, Melan A. CONCLUSION: To our knowledge, only one case of orbital myolipoma has been reported. 12920528 Human
melan a myolipoma Angiomyolipoma was excluded by negative staining for HMB45, Melan A. CONCLUSION: To our knowledge, only one case of orbital myolipoma has been reported. 12920528 Human
mart-1 melanoma Conversely, significant immunization (detected as increased antigen-specific CTL activity in peripheral blood) was obtained by vaccinating HLA-A2.1+ melanoma patients with the immunodominant epitope (residues 27-35) of the differentiation antigen MART-1, 9419448 Human
melan-a tumors Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. 9422316 Human
mart-1 tumors Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. 9422316 Human
melan-a sertoli-leydig cell tumors However, here we report the presence of immunoreactivity for A103, an antibody to Melan-A, in five adrenocortical adenomas, 16 primary and 13 metastatic adrenocortical carcinomas, four Leydig cell tumors of the testis, and three Sertoli-Leydig cell tumors 9422316 Human
melan-a adrenocortical adenomas However, here we report the presence of immunoreactivity for A103, an antibody to Melan-A, in five adrenocortical adenomas, 16 primary and 13 metastatic adrenocortical carcinomas, four Leydig cell tumors of the testis, and three Sertoli-Leydig cell tumors 9422316 Human
melan-a metastatic adrenocortical carcinomas However, here we report the presence of immunoreactivity for A103, an antibody to Melan-A, in five adrenocortical adenomas, 16 primary and 13 metastatic adrenocortical carcinomas, four Leydig cell tumors of the testis, and three Sertoli-Leydig cell tumors 9422316 Human
melan-a leydig cell tumors However, here we report the presence of immunoreactivity for A103, an antibody to Melan-A, in five adrenocortical adenomas, 16 primary and 13 metastatic adrenocortical carcinomas, four Leydig cell tumors of the testis, and three Sertoli-Leydig cell tumors 9422316 Human
mart-1 melanoma Currently, a number of experimental immunotherapies for melanoma are directed against the MAA tyrosinase, MART-1, and gp100. 9456433 Human
mart-1 melanoma In several cases, loss of one MAA was not associated with loss of the other MAA, suggesting that MART-1 can represent a useful additional marker for the diagnosis of melanoma in gp100 (HMB45)-negative lesions. 9466650 Human
mart-1 tumor The expression by DC of MART-1 MAA after viral infection was sufficient to generate CD8+ T lymphocytes that recognized naturally processed epitopes on tumor cells in 10 of 11 patients. 9524710 Human
melan-a malignant melanoma Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. 9543670 Human
melan-a melanoma Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. 9543670 Human
melan-a melanoma Of the two more specific melanocytic markers melan-A stains the majority of benign and malignant lesions diffusely but with occasional patchy positivity only in some secondary melanoma deposits and with little staining of desmoplastic/spindle cell melanom 9543670 Human
melan-a spindle-cell melanomas Of the two more specific melanocytic markers melan-A stains the majority of benign and malignant lesions diffusely but with occasional patchy positivity only in some secondary melanoma deposits and with little staining of desmoplastic/spindle cell melanom 9543670 Human
melan-a desmoplastic melanomas CONCLUSIONS: Melan-A is a useful addition to antibody panels as it is apparently specific for melanocytic lesions and is more sensitive than HMB-45; however, it has less value than S100 in the detection of spindle cell and desmoplastic melanomas. 9543670 Human
mart-1 melanoma Rotating stimulation of T cells with the three B7-expressing cell lines led to the generation of T-cell lines that were cytolytic for HLA-A2+ melanoma cells and other HLA-A2+ targets that were pulsed with HLA-A2-restricted MART-1 peptides. 9551360 Human
melan-a medullary tumors The role of calretinin, inhibin, melan-A, BCL-2, and C-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. 12808065 Human
melan-a adrenal cortical tumors Previous studies have shown inhibin, melan-A, and BCL-2 to be useful markers for adrenal cortical tumors. 12808065 Human
melan-a adrenal cortical tumors In this study, 28 adrenal cortical tumors (12 carcinomas, 16 adenomas), 20 pheochromocytomas, and 20 extraadrenal paragangliomas were evaluated for calretinin, inhibin, melan-A, BCL-2, and c-kit expression by standard immunohistochemical assays on paraffi 12808065 NA
melan-a carcinomas In this study, 28 adrenal cortical tumors (12 carcinomas, 16 adenomas), 20 pheochromocytomas, and 20 extraadrenal paragangliomas were evaluated for calretinin, inhibin, melan-A, BCL-2, and c-kit expression by standard immunohistochemical assays on paraffi 12808065 NA
melan-a adenomas In this study, 28 adrenal cortical tumors (12 carcinomas, 16 adenomas), 20 pheochromocytomas, and 20 extraadrenal paragangliomas were evaluated for calretinin, inhibin, melan-A, BCL-2, and c-kit expression by standard immunohistochemical assays on paraffi 12808065 NA
melan-a adrenal cortical tumors The percentage of immunoreactivity in adrenal cortical tumors was as follows: calretinin, 96%; melan-A, 89%; inhibin, 92%; BCL-2, 20%; and c-kit, 5%. 12808065 Human
melan-a adrenal tumors Like melan-A and inhibin, calretinin is also a very specific marker in differentiating cortical from medullary adrenal tumors. 12808065 Human
mart-1 melanoma EXPERIMENTAL DESIGN: We measured the presence of several markers of melanoma cells in the peripheral blood of 118 patients with resected stage IIb, III, or IV melanoma before and after immunotherapy with a polyvalent, shed antigen, melanoma vaccine using 12684425 Human
mart-1 metastases PATIENTS AND METHODS: We performed prospective studies on 276 patients with primary melanoma and regional lymph node (LN) metastases to assess the predictive value of PCR detection of tyrosinase and melanoma antigen recognized by T cells-1 (MART-1) in the 9586889 NA
mart-1 melanoma PATIENTS AND METHODS: We performed prospective studies on 276 patients with primary melanoma and regional lymph node (LN) metastases to assess the predictive value of PCR detection of tyrosinase and melanoma antigen recognized by T cells-1 (MART-1) in the 9586889 NA
mart-1 melanoma Assays within 3 months of surgery predicted recurrence from melanoma in 66% of the latter (tests for tyrosinase alone detected 51% and MART-1 alone 21% of the patients). 9586889 Human
melan a melanoma The self-peptide MART1(27-35) derives from the melanocyte/melanoma protein Melan A/MART1 and is a target epitope of CD8+ T cells, commonly recovered from tumor-infiltrating lymphocytes of HLA-A2.1+ melanoma patients. 9622085 Human
mart1 melanoma The self-peptide MART1(27-35) derives from the melanocyte/melanoma protein Melan A/MART1 and is a target epitope of CD8+ T cells, commonly recovered from tumor-infiltrating lymphocytes of HLA-A2.1+ melanoma patients. 9622085 Human
mart-1 tumor The effectiveness of adoptive transfer into patients of cytotoxic T lymphocytes recognizing the melanosomal antigens, the significant correlation between vitiligo development and clinical response in patients receiving IL-2-based immunotherapies, and the 9672845 Human
melan a malignant melanoma Melan A (MART-1): a new monoclonal antibody for malignant melanoma diagnosis. 9684410 Human
mart-1 malignant melanoma Melan A (MART-1): a new monoclonal antibody for malignant melanoma diagnosis. 9684410 Human
mart-1 melanoma To establish a mouse model for the use of these 'self' antigens as targets for anti-tumor immune responses, we have employed the mouse homologues of the human melanoma antigens Tyrosinase, Tyrosinase Related Protein-1 (TRP-1), gp100, and MART-1. 9692858 Human
mart-1 melanoma The sera that we generated specifically for TRP-1, gp100, and MART-1 recognized extracts of the spontaneous murine melanoma, B16. 9692858 Human
mart-1 melanoma Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. 9704966 Human
mart-1 melanoma Both tyrosinase and MART-1 are promising markers in the detection of occult melanoma in lymph nodes. 9704966 Human
mart1 primary cutaneous malignant melanoma Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. 9706977 Human
melan-a primary cutaneous malignant melanoma Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. 9706977 Human
mart1 benign melanocytic nevi Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. 9706977 Human
melan-a benign melanocytic nevi Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. 9706977 Human
melan-a primary cutaneous melanomas In this study, we evaluated Melan-A expression immunohistochemically on sections from paraffin-embedded material of 50 benign nevi and 40 primary cutaneous melanomas using the monoclonal antibody A103. 9706977 NA
melan-a metastatic tumors Our results confirm that Melan-A protein is broadly expressed in the majority of benign and malignant melanocytic lesions and suggest that A103 can be helpful diagnostically, not only for metastatic tumors, but also for primary skin lesions. 9706977 Human
melan-a peripheral nerve sheath tumors Its use in distinguishing between melanocytic and peripheral nerve sheath tumors, however, is limited because of the low or absent expression of Melan-A in nevi that underwent neurotization and spindle cell and desmoplastic melanomas. 9706977 Human
melan-a desmoplastic melanomas Its use in distinguishing between melanocytic and peripheral nerve sheath tumors, however, is limited because of the low or absent expression of Melan-A in nevi that underwent neurotization and spindle cell and desmoplastic melanomas. 9706977 Human
mart-1 angiomyolipoma Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. 9720495 Human
mart-1 clear cell sugar tumor Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. 9720495 Human
mart-1 lymphangiomyomatosis Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. 9720495 Human
melan-a metastatic amelanotic melanomas Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. 9720502 Human
melan-a metastatic melanomas The authors retrospectively tested the potential value of paraffin-reactive monoclonal antibodies (A103 against melan-A, T311 against tyrosinase) and antibody KBA62 as immunohistochemical markers for amelanotic metastatic melanomas. 9720502 Human
mart-1 uveal melanoma High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. 9820172 Human
mart-1 cutaneous melanoma In the treatment of cutaneous melanoma, provisional therapeutic strategies have been designed to combat tumour load using T cells that are sensitized with peptides derived from melanoma autoantigens, such as glycoprotein 100 (gp100), melanoma antigen reco 9820172 Human
mart-1 melanoma In the treatment of cutaneous melanoma, provisional therapeutic strategies have been designed to combat tumour load using T cells that are sensitized with peptides derived from melanoma autoantigens, such as glycoprotein 100 (gp100), melanoma antigen reco 9820172 Human
mart-1 tumour In the treatment of cutaneous melanoma, provisional therapeutic strategies have been designed to combat tumour load using T cells that are sensitized with peptides derived from melanoma autoantigens, such as glycoprotein 100 (gp100), melanoma antigen reco 9820172 Human
mart-1 cutaneous melanoma We recently found that gp100, MART-1 and tyrosinase are heterogeneously expressed in human cutaneous melanoma (De Vries et al (1997) Cancer Res 57: 3223-3229). 9820172 Human
mart-1 metastasis Cryostat sections from 11 spindle-type, 21 mixed and epithelioid tumours and four metastasis lesions were stained with antibodies specifically recognizing gp100, MART-1, tyrosinase and TRP-1. 9820172 Human
mart-1 tumours Cryostat sections from 11 spindle-type, 21 mixed and epithelioid tumours and four metastasis lesions were stained with antibodies specifically recognizing gp100, MART-1, tyrosinase and TRP-1. 9820172 Human
mart-1 uveal melanoma High expression of gp100, MART-1 and tyrosinase was found in the uveal melanoma lesions: 80% of the lesions displayed 75-100% positive tumour cells. 9820172 Human
mart-1 tumour High expression of gp100, MART-1 and tyrosinase was found in the uveal melanoma lesions: 80% of the lesions displayed 75-100% positive tumour cells. 9820172 Human
mart-1 melanoma Here, we show that autologous DCs from both HLA-A2-positive melanoma patients and normal healthy individuals that are transduced with an adenoviral vector containing the MART-1 antigen are capable of inducing both MART-1-specific CD8+ and CD4+ T cells in 9850054 Human
mart-1 metastatic melanoma Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. 9862627 Human
mart-1 melanoma Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. 9862627 Human
mart-1 metastatic melanoma BACKGROUND: The characterization of the genes encoding melanoma-associated antigens MART-1 or gp100, recognized by T cells, has opened new possibilities for the development of immunization strategies for patients with metastatic melanoma. 9862627 Human
mart-1 metastatic melanoma With the use of recombinant adenoviruses expressing either MART-1 or gp100 to immunize patients with metastatic melanoma, we evaluated the safety, immunologic, and potential therapeutic aspects of these immunizations. 9862627 Human
mart-1 metastatic melanoma One of 16 patients with metastatic melanoma receiving the recombinant adenovirus MART-1 alone experienced a complete response. 9862627 Human
melan-a melanoma These findings have important implications for the formulation of Melan-A peptide-based vaccines as well as for the monitoring of Melan-A-specific CTL responses in melanoma patients. 9862730 Human
melan-a melanoma CTL responses to Melan-A 9-mer (amino acids 27-35, AAGIGILTV) peptide were detected in 4 out of 16 normal individuals, but in none of the melanoma patients. 9875671 Human
melan-a melanoma No significant responses were observed in either normal individuals or melanoma patients to Melan-A 10-mer (26-35, EAAGIGILTV), two gp1OO epitopes (280-288, YLEPGPVTA; 457466, LLDGTATLRL) and two tyrosinase epitopes (1-9, MLLAVLYCL; 368-376, YMDGMSQV). 9875671 Human
melan-a melanoma Melan-A (27-35)-specific CTL cells generated by normal individuals and melanoma patients recognized both synthetic peptide-pulsed T2 cells and two HLA-A2+, Melan-A+ melanoma cell lines (ME272, LAR1) in an antigen-specific, MHC class I restricted manner. 9875671 Human
mart-1 metastatic melanoma In addition, tumor-reactive CTLs could be induced from PBMCs of patients with metastatic melanoma by in vitro stimulation with HMY-C1R B-cell lines expressing the MART-1 or gp100 epitope-HLA-A*0201 fusion protein. 9000554 Human
mart-1 tumor Tumor cells were positive with IM stains to MART-1 in 78% of cases, HMB45 in 81%, and S-100 in 81%. 9100543 Human
mart1 melanoma Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. 9101410 Mouse
mart1 b16 melanoma To develop a syngeneic animal model for evaluating antigen-specific vaccines in cancer therapy, the murine homologues of the human melanoma antigens MART1 and gp100, which were specifically recognized by tumor-infiltrating lymphocytes from patients with m 9101410 Mouse
mart1 cancer To develop a syngeneic animal model for evaluating antigen-specific vaccines in cancer therapy, the murine homologues of the human melanoma antigens MART1 and gp100, which were specifically recognized by tumor-infiltrating lymphocytes from patients with m 9101410 Human
mart1 melanoma To develop a syngeneic animal model for evaluating antigen-specific vaccines in cancer therapy, the murine homologues of the human melanoma antigens MART1 and gp100, which were specifically recognized by tumor-infiltrating lymphocytes from patients with m 9101410 Mouse
mart1 b16 melanoma Comparison of the DNA sequences of the murine MART1 genes, derived from normal melanocytes, the immortalized nontumorgenic melanocyte line Melan-a and the B16 melanoma, showed all to be identical. 9101410 Mouse
mart1 b16 melanoma Mice immunized with murine MART1 or gp100 using recombinant vaccinia virus failed to produce any detectable T-cell responses or protective immunity against B16 melanoma. 9101410 Mouse
mart-1 malignant melanomas Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. 9101414 Human
mart-1 paraffin-embedded tumors Twenty-three paraffin-embedded tumors were evaluated for MART-1 immunoreactivity both before and after microwave-based antigen retrieval. 9101414 Human
mart-1 malignant melanoma After this comparison, 53 fine-needle aspirates from 43 patients with malignant melanoma were assessed for MART-1 immunoreactivity. 9101414 Human
mart-1 tumors In 13 (25%) of 53 tumors, MART-1 immunoreactivity was more intense in the cytospins, although the differences were marked in only two cases: Microwave-based antigen retrieval renders paraffin-embedded tissues nearly as sensitive as fresh material for use 9101414 Human
mart-1 malignant melanomas This technique will allow the evaluation of MART-1 immunoreactivity in archival malignant melanomas. 9101414 Human
mart-1 tumor infiltrating lymphocytes (til) Two genes encoding human melanoma antigens MART-1 and gp100 recognized by HLA-A2 restricted melanoma reactive CTL derived from tumor infiltrating lymphocytes (TIL) were isolated by cDNA expression cloning methods. 9131386 Human
mart-1 melanoma Two genes encoding human melanoma antigens MART-1 and gp100 recognized by HLA-A2 restricted melanoma reactive CTL derived from tumor infiltrating lymphocytes (TIL) were isolated by cDNA expression cloning methods. 9131386 Human
mart-1 melanoma Multiple unmutated self peptides were identified as T cell epitopes in these melanocyte/melanoma specific proteins (2 from MART-1 and 5 from gp100). 9131386 Human
mart-1 tumor A murine tumor model was developed to evaluate methods of genetic immunization to the human MART-1/Melan-A (MART-1) melanoma antigen. 9230191 Human
mart-1 fibrosarcoma A poorly immunogenic murine fibrosarcoma line (NFSA) was stably transfected with the MART-1 gene. 9230191 Human
mart-1 melanoma Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. 9242453 Human
mart-1 tumor In recent years, it has become evident that T cells can recognize peptides of melanocytic lineage antigens such as gp100, MART-1, and tyrosinase at the tumor cell surface and can subsequently destroy these cells. 9242453 Human
mart-1 central nervous system tumor MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. 12952283 Human
mart-1 b16 melanoma In this study, a recombinant adenovirus vector encoding the melanoma-associated antigen, MART-1, was used to transduce murine DCs, which were then tested for their ability to activate cytotoxic T lymphocytes (CTLs) and induce protective immunity against B 12952283 NA
mart-1 tumor In this study, a recombinant adenovirus vector encoding the melanoma-associated antigen, MART-1, was used to transduce murine DCs, which were then tested for their ability to activate cytotoxic T lymphocytes (CTLs) and induce protective immunity against B 12952283 NA
mart-1 melanoma Using the B16 murine melanoma, which naturally expresses the MART-1 antigen, all the mice were then challenged intracranially with viable, unmodified syngeneic B16 tumor cells 7 days later. 12952283 Human
mart-1 tumor Using the B16 murine melanoma, which naturally expresses the MART-1 antigen, all the mice were then challenged intracranially with viable, unmodified syngeneic B16 tumor cells 7 days later. 12952283 Human
mart-1 melanoma HLA-A2+ DC and MART-1 negative/A2+ melanoma cells transfected with the A27L RNA were recognized and killed by MART-1-specific CTL, suggesting that these APC efficiently processed the A27L RNA and presented correct MART-1-specific epitope(s). 14609574 Human
melan a other solid tumors Pmel 17 and Melan A have led to vaccines developed against differentiation antigens expressed in other solid tumors. 9396616 Human
mart-1 metastatic melanoma Differential expression of MART-1 in primary and metastatic melanoma lesions. 9409451 Human
mart-1 metastatic melanoma MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. 9409451 Human
mart-1 melanoma MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. 9409451 Human
mart-1 pigmented nevi MART-1 was expressed homogeneously in primary melanoma and pigmented nevi, whereas it was heterogeneously expressed in metastatic melanoma lesions. 9409451 Human
mart-1 melanoma The level of expression of MART-1 in primary melanoma lesions did not correlate with any clinicopathologic parameters. 9409451 Human
mart1 cancer Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. 8543823 Human
mart1 tumor Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. 8543823 Human
mart1 melanoma The human melanoma tumor Ags, MART1 and gp100, are specifically recognized by HLA-A2-restricted CD8+ CTLs derived from melanoma patients and appear to be involved in tumor regression. 8543823 Human
mart1 tumor The human melanoma tumor Ags, MART1 and gp100, are specifically recognized by HLA-A2-restricted CD8+ CTLs derived from melanoma patients and appear to be involved in tumor regression. 8543823 Human
mart1 melanoma Because of the suspected homology between the human MART1 and gp100 genes and their murine counterparts, we immunized C57BL/6 mice with these recombinant adenoviruses and demonstrated that immunization with Ad2CMV-gp100 could protect mice from murine mela 8543823 Mouse
melan-a melanoma Immunoblotting results with A103 showed a 20-22-kDa doublet In Melan-A mRNA positive melanoma cell lines and no reactivity with Melan-A mRNA-negative cell lines. 8650193 Human
melan-a melanoma Immunocytochemical assays on cultured melanoma cells showed specific and uniform cytoplasmic staining in Melan-A mRNA-positive cell lines. 8650193 Human
melan-a melanoma Analysis of 21 melanoma specimens showed homogenous staining of tumor cell cytoplasm in 16 of 17 Melan-A mRNA-positive cases and no reactivity with the three Melan-A mRNA-negative cases. 8650193 Human
melan-a tumor Analysis of 21 melanoma specimens showed homogenous staining of tumor cell cytoplasm in 16 of 17 Melan-A mRNA-positive cases and no reactivity with the three Melan-A mRNA-negative cases. 8650193 Human
mart-1 melanoma Here we analyzed the responses to synthetic peptides of HLA-A2.1-restricted CTL clones specific for melanoma antigens MART-1 and NA17-A. 8642353 Human
mart-1 tumor Among the immunomodulators, the T-cell antigen MART-1 and the protease inhibitor alpha2-macroglobulin were detected in the melanocyte cell line but not in the tumor cells. 8674069 Human
mart-1 melanoma RNA slot blot hybridization on a larger panel of melanocyte and melanoma cell lines confirmed differential expression of 15 of 42 genes including MART-1, alpha2-macroglobulin, and CD59. 8674069 Human
mart-1 cancers These antigens are classified as 1) melanocyte specific melanosomal proteins (MART-1, gp100, tyrosinase and TRP-1), 2) proteins expressed in testis and a variety of cancers (MAGE-1, MAGE-3, BAGE and GAGE), 3) tumor specific mutated proteins (beta-catenin, 8683899 Human
mart-1 tumor These antigens are classified as 1) melanocyte specific melanosomal proteins (MART-1, gp100, tyrosinase and TRP-1), 2) proteins expressed in testis and a variety of cancers (MAGE-1, MAGE-3, BAGE and GAGE), 3) tumor specific mutated proteins (beta-catenin, 8683899 Human
mart-1 metastatic melanoma Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. 8811494 Human
mart-1 cancer None of the nonmelanoma cancer lines tested stained for MART-1 or gp100. 8811494 Human
mart-1 melanoma Analysis of melanoma lesions by immunohistochemistry showed significant heterogeneity of expression of both MART-1 and gp100 MAA either as a percentage of cells expressing MAA or as intensity of expression. 8811494 Human
mart-1 melanoma In this study, we compared the characteristics of the cytotoxic T lymphocyte (CTL) response to MART-1 in PBMC from 13 HLA-A2 melanoma patients with PBMC from 9 normal healthy donors stimulated in vitro with MART-1(27-35) (AAGIGILTV) or FluM1(58-66) (GILGF 8877721 NA
mart-1 neuroblastoma Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. 8900375 Human
mart-1 tumors The MAGE-1 and MAGE-3 genes are expressed in tumors of different histotypes but not in normal adult tissues (with the exception of testis), while the MART-1 gene appears to be selectively expressed in melanoma. 8900375 Human
mart-1 melanoma The MAGE-1 and MAGE-3 genes are expressed in tumors of different histotypes but not in normal adult tissues (with the exception of testis), while the MART-1 gene appears to be selectively expressed in melanoma. 8900375 Human
mart-1 cancer MAGE-1, MAGE-3 and MART-1 antigens may therefore constitute useful targets for specific anti-tumor immunization of cancer patients. 8900375 Human
mart-1 tumor Here we have investigated the expression of MAGE-1, MAGE-3 and MART-1 in 11 neuroblastoma (NB) cell lines and 73 NB tumor masses. 8900375 Human
mart-1 neuroblastoma Here we have investigated the expression of MAGE-1, MAGE-3 and MART-1 in 11 neuroblastoma (NB) cell lines and 73 NB tumor masses. 8900375 Human
mart-1 tumor No expression of the MART-1 gene was observed in any cell line or tumor sample. 8900375 Human
mart-1 melanoma We focused on three known differentiation MAAs: tyrosinase (TYR), TYR-related protein 2 (TRP-2), and melanoma antigen recognized by T cells 1 (MART-1); all three of them are known to induce immune responses in melanoma patients and are frequently expresse 12543800 Human
mart-1 melanomas We focused on three known differentiation MAAs: tyrosinase (TYR), TYR-related protein 2 (TRP-2), and melanoma antigen recognized by T cells 1 (MART-1); all three of them are known to induce immune responses in melanoma patients and are frequently expresse 12543800 Human
mart-1 melanoma tumor In addition, these CTLs recognized the T2 cell line pulsed exogenously with the peptide MART-1(27-35), which is the nine-amino acid immunodominant epitope of the MART-1 Ag recognized on melanoma tumor cells by nearly all HLA-A2-restricted TIL. 7814882 Human
mart-1 melanoma Recognition of HLA-A2+ melanoma cell lines by the Jurkat clone 5 TCR+ cells, however, did not occur without the addition of exogenous MART-1 peptide. 7531614 Human
mart-1 melanoma Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. 7868898 Human
mart-1 melanoma MART-1 is an Ag expressed on melanomas and melanocytes, and is recognized by the majority of HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes (TIL) from melanoma patients. 7868898 Human
mart-1 melanomas MART-1 is an Ag expressed on melanomas and melanocytes, and is recognized by the majority of HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes (TIL) from melanoma patients. 7868898 Human
mart-1 melanoma CTL generated with MART-1(27-35) also lysed uncultured HLA-A2+ melanoma cells derived from tumor biopsies, indicating that this MART-1 epitope is likely to be expressed in association with HLA-A2 on the surface of tumor cells in vivo. 7868898 Human
mart-1 tumor CTL generated with MART-1(27-35) also lysed uncultured HLA-A2+ melanoma cells derived from tumor biopsies, indicating that this MART-1 epitope is likely to be expressed in association with HLA-A2 on the surface of tumor cells in vivo. 7868898 Human
mart-1 melanoma Four of ten HLA-A2-restricted melanoma specific CTL that were derived from tumor-infiltrating lymphocytes (TIL) and administered to patients recognized the gp100 melanoma Ag and nine of ten recognized the MART-1 Ag. 7706734 Human
mart-1 metastatic melanoma MART-1, beta-actin, and beta(2)-microglobulin mRNAs were consistently detected in FFPE metastatic melanoma even after fixation for up to 3 weeks, although the total mRNA detected was markedly reduced in fixed compared with fresh tissues (up to 99%). 12552078 Human
melan-a tumor Immunohistochemically, the tumor cells were positive for HMB-45 but negative for epithelial markers, Melan-A, and S100 protein. 12562263 Human
mart-1 tumor A marked heterogeneity in the susceptibility to lysis by A42 was observed in tumor clones and was not due to heterogeneous expression of MART-1 by the clones or loss of accessory molecules involved in the lymphocyte-target interaction. 7541714 Human
mart-1 melanoma EXPERIMENTAL DESIGN: We measured CD8+ T-cell responses to gp100, MART-1, MAGE-3, and tyrosinase by enzyme-linked immunospot assay in peripheral blood of 131 HLA-A*01- or HLA-A*02-positive melanoma patients before and after immunization to a polyvalent, sh 12576432 Human
melan-a melanoma EXPERIMENTAL DESIGN: Three melanoma patients were immunized with a Melan-A peptide analog that binds more strongly to HLA-A*0201 and is more immunogenic than the natural sequence. 12576434 Human
mart-1 melanoma Histologically, the lesion had the appearance of an anaplastic neoplasm, and a panel of immunohistochemical markers including vimentin, MART-1, S100 protein, HMB-45, smooth muscle actin, common muscle actin, desmin, CD31, CD34, CD68, EMA and cytokeratins, 12581389 Human
mart-1 neoplasm Histologically, the lesion had the appearance of an anaplastic neoplasm, and a panel of immunohistochemical markers including vimentin, MART-1, S100 protein, HMB-45, smooth muscle actin, common muscle actin, desmin, CD31, CD34, CD68, EMA and cytokeratins, 12581389 Human
mart-1 epithelial neoplasms Histologically, the lesion had the appearance of an anaplastic neoplasm, and a panel of immunohistochemical markers including vimentin, MART-1, S100 protein, HMB-45, smooth muscle actin, common muscle actin, desmin, CD31, CD34, CD68, EMA and cytokeratins, 12581389 Human
mart-1 recurrent tumor Retrospective immunohistochemical staining with newly commercially available antibodies including MART-1 was done on both the original and the recurrent tumor, confirming the diagnosis of uterine PEComa. 13678746 Human
melan a melanoma RIHC for S-100 protein, HMB45, and a melanoma marker cocktail (melan A, HMB45, and tyrosinase) was performed on 71 SLNs obtained from 28 patients with MM. 14506642 Human
mart-1 metastases Thus lymphocytes reactive with the MART-1 melanoma antigen appeared to be widely distributed in diverse metastases in this patient. 8680654 Human
mart-1 tumor infiltrating lymphocytes Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. 7516411 Human
mart-1 melanoma Four melanoma proteins, MART-1, gp100, tyrosinase, and tyrosinase-related protein-1 (gp75) were evaluated for recognition by HLA-A2-restricted melanoma-specific cytotoxic T lymphocytes (CTLs) derived from the tumor-infiltrating lymphocytes (TIL) of 10 dif 7516411 Human
mart-1 melanoma In this study we investigated the level of efficacy of a MART-1/Melan-A-specific CD8+ T cell clone against its autologous melanoma in a severe combined immunodeficiency (SCID) mouse model, in which the tumor cells expressed in vivo heterogeneous and subop 12645955 NA
mart-1 tumor In this study we investigated the level of efficacy of a MART-1/Melan-A-specific CD8+ T cell clone against its autologous melanoma in a severe combined immunodeficiency (SCID) mouse model, in which the tumor cells expressed in vivo heterogeneous and subop 12645955 NA
melan-a tumors We also tested for CD99, Melan-A (A103), and S-100, other markers reported to be positive in these tumors. 12649671 Human
melan-a tumors All six tumors were positive for Melan-A (A103), but in general the staining was less diffuse than with calretinin. 12649671 Human
mart-1 tumors All of the tumors were essentially negative for MART-1 (Ab3). 12649671 Human
melan-a tumors The consistent diffuse staining of the tumors in this study for calretinin, in comparison to inhibin and Melan-A (A103), suggests that it is a sensitive marker for SCTs, NOS. 12649671 Human
mart-1 melanoma MART-1 (Ab3) immunostaining may be useful for cases in which melanoma is considered in the differential diagnosis. 12649671 Human
melan-a melanoma The two melanoma lines also maintained susceptibility to lysis by lymphokine-activated killer (LAK) cells and by a HLA-A2-restricted melanoma-specific cytotoxic T lymphocyte (CTL) clone recognizing the melanoma antigen (Melan-A). 7833372 Human
melan-a melanoma In particular, melan-A, acid phosphatase 5, dopachrome tautomerase, S100-beta and acid ceramidase were found to be among the most important genes for melanoma. 12675527 Human
mart-1 melanoma Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. 12735792 Human
melan-a melanoma Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. 12735792 Human
mart-1 cutaneous melanoma Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. 12735792 Human
melan-a cutaneous melanoma Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. 12735792 Human
mart-1 melanoma BACKGROUND: MART-1, Melan-A, and Tyrosinase have shown encouraging results for evaluation of melanoma micrometastases in sentinel lymph nodes, as compared to conventionally used S-100 protein and HMB-45. 12735792 Human
melan-a melanoma BACKGROUND: MART-1, Melan-A, and Tyrosinase have shown encouraging results for evaluation of melanoma micrometastases in sentinel lymph nodes, as compared to conventionally used S-100 protein and HMB-45. 12735792 Human
mart-1 melanoma METHODS: We prepared a combination of monoclonal antibodies to these three immunomarkers in optimized dilutions (MART-1, clone M2-7C10, dilution 1:500; Melan-A, clone A103, dilution 1:100; and Tyrosinase, clone T311, dilution 1:50) and designated it as &a 12735792 NA
melan-a melanoma METHODS: We prepared a combination of monoclonal antibodies to these three immunomarkers in optimized dilutions (MART-1, clone M2-7C10, dilution 1:500; Melan-A, clone A103, dilution 1:100; and Tyrosinase, clone T311, dilution 1:50) and designated it as &a 12735792 NA
mart-1 melanoma Of these 78 slices, 21 were positive for melanoma micrometastases with MART-1 and Melan-A individually. 12735792 Human
melan-a melanoma Of these 78 slices, 21 were positive for melanoma micrometastases with MART-1 and Melan-A individually. 12735792 Human
mart-1 melanoma Thus, MART-1 and Melan-A could not detect melanoma micrometastases individually in 16% (4/25) of slices positive with the cocktail. 12735792 Human
melan-a melanoma Thus, MART-1 and Melan-A could not detect melanoma micrometastases individually in 16% (4/25) of slices positive with the cocktail. 12735792 Human
melan a mucosal malignant melanomas Immunohistochemical studies confirmed the diagnosis of sinonasal tract mucosal malignant melanomas with positive reactions for S-100 protein, tyrosinase, HMB-45, melan A, and microphthalmia transcription factor. 12717245 Human
melan-a tumor Immunohistochemically, the tumor cells were typically positive for HMB-45 and smooth muscle actin but negative for S-100 protein, Melan-A, desmin, and pan-cytokeratin. 12717254 Human
melan-a renal angiomyolipoma HMB45 and melan-A expression in renal angiomyolipoma and their significance for the diagnosis. 12729361 Human
melan-a renal angiomyolipoma AIMS AND BACKGROUND: The melanosome-associated proteins, also called HMB45 and melan-A, are also present in renal angiomyolipoma. 12729361 Human
melan-a renal angiomyolipoma The aim of the present study was to evaluate the expression of HMB45 and melan-A in mesenchymal cells of renal angiomyolipoma and to investigate their significance in the differential diagnosis. 12729361 Human
melan-a epithelial tumors CONCLUSIONS: It was concluded that HMB45 and melan-A reactivity is a useful tool to distinguish renal angiomyolipomas from other primary and secondary mesenchymal and primary epithelial tumors. 12729361 Human
melan-a renal angiomyolipoma Melan-A and HMB45 share similar specificities for renal angiomyolipoma. 12729361 Human
mart-1 tumor Microscopically, the tumor cells were medium-sized, predominantly oval, relatively monomorphic, diffusely immunoreactive for S-100-protein, and negative for CD117, CD34, HMB-45, and Mart-1. 12754623 Human
melan-a melanoma The RT-PCR assay was performed by use of tyrosinase, Melan-A, gp100, tyrosinase-related protein 2 (TRP-2), or melanoma antigen-encoding gene B (MAGE-B)-specific primers. 12755292 Human
melan-a melanoma Tyrosinase, Melan-A, gp100, and TRP-2 mRNAs were detected in tumor biopsy specimens and in 2 of 5 LN aspirates from dogs with melanoma, suggesting metastatic spread in those 2 dogs. 12755292 others
melan-a tumor Tyrosinase, Melan-A, gp100, and TRP-2 mRNAs were detected in tumor biopsy specimens and in 2 of 5 LN aspirates from dogs with melanoma, suggesting metastatic spread in those 2 dogs. 12755292 others
mart1 tumour Furthermore, we show that fixed E. coli/LLO expressing the well-characterised human melanoma antigen, MART1, efficiently deliver the HLA-A2-restricted MART1(27-35) epitope for processing and presentation on human MoDCs, suggesting the potential of this sy 12767067 Human
melan-a melanoma Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. 12805336 Human
melan-a melanoma A phase II study of immunization with Melan-A peptide-pulsed PBMC + rhIL-12 was conducted in 20 patients with advanced melanoma. 12805336 Human
mlana melanoma The clinically important melanoma diagnostic antibodies HMB-45, melan-A, and MITF (D5) recognize gene products of the melanocyte-lineage genes SILV/PMEL17/GP100, MLANA/MART1, and MITF, respectively. 12819038 Human
mart1 melanoma The clinically important melanoma diagnostic antibodies HMB-45, melan-A, and MITF (D5) recognize gene products of the melanocyte-lineage genes SILV/PMEL17/GP100, MLANA/MART1, and MITF, respectively. 12819038 Human
melan-a melanoma The clinically important melanoma diagnostic antibodies HMB-45, melan-A, and MITF (D5) recognize gene products of the melanocyte-lineage genes SILV/PMEL17/GP100, MLANA/MART1, and MITF, respectively. 12819038 Human
mlana melanoma In addition, MITF regulated their promoter/enhancer regions in reporter assays, and up- or down-regulation of MITF produced corresponding modulation of endogenous SILV and MLANA in melanoma cells. 12819038 Human
melan a tumors In addition, tumors were examined for expression of vimentin, cytokeratin, smooth muscle actin, desmin, melan A, neural cell adhesion molecule, S-100, glial fibrillary acidic protein, nerve growth factor receptor, and collagen type IV. 12824506 Human
mart1 primary tumors Antibodies against AE1/AE3 cytokeratin, vimentin, and melanA/MART1 stained 29 of 30 (97%), 29 of 30 (97%), and 12 of 27 (44%) primary tumors, respectively. 12824515 Human
mart-1 stage iii melanoma PATIENTS AND METHODS: After complete surgical resection, prospectively collected cryopreserved peripheral-blood lymphocyte specimens (n = 90) from the serial bleeds of 30 patients with AJCC stage III melanoma were studied by MM-RT-PCR, using the markers t 12829676 NA
mart-1 primary cutaneous melanoma 1158 sentinel lymph nodes (SLNs), excised from patients with primary cutaneous melanoma, were assessed pathologically using histology with immunohistochemistry (IHC) on all nodes, and RT-PCR for Mart-1 and tyrosinase on 55 nodes. 12845627 Human
mart-1 melanoma A significant decrease in the expression of the melanoma common tumour antigen MART-1 in the last primary tumour from multiple melanoma patients (median 8%, mean 24) versus matched single melanoma patients (median 79%, mean 68) (p=0.0041) and in the last 12845635 Human
mart-1 primary tumour A significant decrease in the expression of the melanoma common tumour antigen MART-1 in the last primary tumour from multiple melanoma patients (median 8%, mean 24) versus matched single melanoma patients (median 79%, mean 68) (p=0.0041) and in the last 12845635 Human
mart-1 tumour A significant decrease in the expression of the melanoma common tumour antigen MART-1 in the last primary tumour from multiple melanoma patients (median 8%, mean 24) versus matched single melanoma patients (median 79%, mean 68) (p=0.0041) and in the last 12845635 Human
mart-1 melanoma Metastases from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 loss (median 0%, mean 11) compared with matched metastases from patients with non-regressing primary melanoma (media 12845635 Human
mart-1 occult primary melanoma Metastases from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 loss (median 0%, mean 11) compared with matched metastases from patients with non-regressing primary melanoma (media 12845635 Human
mart-1 melanomas Metastases from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 loss (median 0%, mean 11) compared with matched metastases from patients with non-regressing primary melanoma (media 12845635 Human
mart-1 metastases Metastases from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 loss (median 0%, mean 11) compared with matched metastases from patients with non-regressing primary melanoma (media 12845635 Human
melan-a malignant melanoma Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. 12862418 Human
melan-a melanoma Subjects had evaluable stage III or IV melanoma which expressed Melan-A by RT-PCR or immunohistochemistry. 12862418 Human
melan-a tumors Biopsies of accessible tumors showed infiltration with CD4+ and CD8+ lymphocytes capable of lysing Melan-A peptide-pulsed targets in vitro. 12862418 Human
mart-1 malignancy Thus, we have identified a gene encoding a melanocyte lineage-specific protein (MART-1; melanoma antigen recognized by T cells 1) that is a widely shared melanoma antigen recognized by the T lymphocytes of patients with established malignancy. 8170938 Human
mart-1 paraffin-embedded tumour In the present study conducted by the Melanoma Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-MCG), immunohistochemical staining for gp100 (antibodies NKI-beteb and HMB-45), MART-1 (A103), tyrosinase (T311), and 11169510 Human
mart-1 primary tumours In the present study conducted by the Melanoma Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC-MCG), immunohistochemical staining for gp100 (antibodies NKI-beteb and HMB-45), MART-1 (A103), tyrosinase (T311), and 11169510 Human
mart-1 melanoma tumour The apparently stable expression of most of the melanoma antigens, and the small contribution of decreased expression in melanoma tumour progression, supports the rationale for immunotherapy based on the melanoma immunogens gp100, MART-1, and tyrosinase. 11169510 Human
mart-1 cns metastases The correlation between CSF RT-PCR positivity of MART-1 and/or MAGE-3 and the development of CNS metastases at 3 mo was significant (p = 0.04). 11511319 Human
mart-1 metastatic tumours Metastatic tumours from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 tumour-loss variants (median 0% MART-1-positive tumour) compared to matched metastatic tumours from patients 11745443 Human
mart-1 skin melanomas Metastatic tumours from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 tumour-loss variants (median 0% MART-1-positive tumour) compared to matched metastatic tumours from patients 11745443 Human
mart-1 skin melanomas AIMS: To detect micrometastases in the sentinel lymph nodes (SLN) of melanoma patients the authors analysed 52 lymph nodes (47 SLNs and five non-sentinel) and 17 corresponding primary skin melanomas using reverse transcriptase-polymerase chain reaction as 11952287 NA
mart-1 nevus The melanocytic cells of the nevus cell aggregates expressed S-100 protein and/or MART-1 but not gp100 protein (HMB-45). 12717252 Human
mart-1 skin melanomas Metastases from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 loss (median 0%, mean 11) compared with matched metastases from patients with non-regressing primary melanoma (media 12845635 Human
mart-1 pecoma Retrospective immunohistochemical staining with newly commercially available antibodies including MART-1 was done on both the original and the recurrent tumor, confirming the diagnosis of uterine PEComa. 13678746 Human
mart-1 atypical fibroxanthoma HMB-45 (gp103) and MART-1 expression within giant cells in an atypical fibroxanthoma: a case report. 14984584 Human
mart-1 neoplasm RESULTS: Microscopic examination revealed a neoplasm composed of pleomorphic epithelioid cells with atypical features, immunoreactive for HMB-45, MART-1, actin, vimentin and calponin, while S100 protein and desmin stains were negative. 14987234 Human
mart-1 tumor The tumor cells were strongly immunoreactive with S100 protein, vimentin, and CD56, and were focally reactive with Mart-1. 15163228 Human
mart-1 melanomas Our goal was to determine the consistency of positive staining in melanomas on the basis of the usefulness of MAGE-1 in comparison with tyrosinase and MART-1. 15223957 Human
mart-1 malignant melanomas We studied 56 malignant melanomas using immunohistochemical markers to MAGE-1, tyrosinase, MART-1, HMB-45, and S-100. 15223957 NA
mart-1 metastatic malignant melanomas S-100 protein, tyrosinase, and MART-1 immunomarkers were more frequently positive in our melanoma cases and appear to constitute a useful panel of markers to aid in the diagnosis of metastatic malignant melanomas, especially in patients with an unknown pr 15223957 Human
mart-1 melanoma S-100 protein, tyrosinase, and MART-1 immunomarkers were more frequently positive in our melanoma cases and appear to constitute a useful panel of markers to aid in the diagnosis of metastatic malignant melanomas, especially in patients with an unknown pr 15223957 Human
mart-1 b16 melanoma The ability of these same DCs to generate protective immunity against B16 melanoma, which expresses murine MART-1, was also abrogated by radiation. 15294960 Mouse
mart-1 tumor The authors describe a patient who experienced recurrence of metastatic melanoma after an initial dramatic response to immunotherapy using peptides derived from gp100, MART-1, and tyrosinase emulsified in incomplete Freund's adjuvant, and present dat 15076135 Human
mart-1 metastatic melanoma The authors describe a patient who experienced recurrence of metastatic melanoma after an initial dramatic response to immunotherapy using peptides derived from gp100, MART-1, and tyrosinase emulsified in incomplete Freund's adjuvant, and present dat 15076135 Human
mart-1 advanced cancer Maturation by AdV transduction alone leads to efficient stimulation of antigen-specific T cells from both healthy donors and patients with advanced cancer using two defined human tumor-associated antigens, MART-1 and AFP. 15076136 Human
mart-1 metastatic tumors Melan-A, also known as MART-1, is an additional melanocytic marker and has proved to be useful in identifying metastatic tumors of melanocytic origin. 15365366 Human
mart-1 melanoma Adenoviral vectors were used to express the tumor-associated-but-self-antigen MART-1 fused to HSV VP22 in MART-1-negative A375 melanoma cells and in DC. 15368298 Human
mart-1 melanoma Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. 15457091 Human
mart-1 melanoma The objective of this study was to characterize the molecular profiles of melanoma cells in peripheral blood, lymph nodes and metastatic tissues, employing the messenger RNA (mRNA) expression of tyrosinase, melanoma-inhibiting activity (MIA) and melanoma 15457091 Human
mart-1 metastases Tyrosinase, MIA and MART-1 were expressed in 59%, 76% and 76% of the metastases, respectively. 15457091 Human
mart-1 melanoma Furthermore, melanoma lesions may be negative for the expression of antigens such as MART-1, and discrepancies in expression patterns between peripheral blood and metastatic tissues may occur, especially for this marker. 15457091 Human
mart-1 breast cancer We analyzed MART-1, S-100, MBP, and CD63 for melanoma and p53, MUC1, cyclin B1, HER-2/neu, and CEA for breast cancer. 15542372 Human
mart-1 melanoma We analyzed MART-1, S-100, MBP, and CD63 for melanoma and p53, MUC1, cyclin B1, HER-2/neu, and CEA for breast cancer. 15542372 Human
mart-1 melanoma Using five defined human T cell lines derived from melanoma patients, allogeneic DCs of HLA-A2, HLA-DR4 and HLA-DR7 haplotypes fused with MART-1, gp100, tyrosinase and TRP-2 expressing 888 mel melanoma cells were analysed for their ability to stimulate sp 15603192 Human
mart-1 melanoma PURPOSE: Nineteen patients with high-risk resected stage III and IV melanoma were immunized with three tumor antigen epitope peptides from gp100, MART-1, and tyrosinase emulsified with adjuvant Montanide ISA 51 and received a fully human anti-cytotoxic T- 15613700 NA
mart-1 tumor The tumor cells were reactive for S-100 protein, HMB-45, and MART-1. 15677980 Human
mart-1 melanoma Pathologic Assessment of Melanoma Sentinel Nodes: A Role for Molecular Analysis Using Quantitative Real-Time Reverse Transcription-PCR for MART-1 and Tyrosinase Messenger RNA. 15746042 Human
mart-1 metastasis We investigated whether quantitative reverse transcription-PCR (RT-PCR) detection of MART-1 and tyrosinase mRNAs could improve this specificity and contribute to SN assessment.EXPERIMENTAL DESIGN: Two hundred twenty SNs from 95 melanoma patients analyzed 15746042 Human
mart-1 melanoma We investigated whether quantitative reverse transcription-PCR (RT-PCR) detection of MART-1 and tyrosinase mRNAs could improve this specificity and contribute to SN assessment.EXPERIMENTAL DESIGN: Two hundred twenty SNs from 95 melanoma patients analyzed 15746042 Human
mart-1 metastasis Median MART-1 and tyrosinase mRNA levels in SNs were significantly different in patients with metastasis compared with patients with BNIs (P < 0.05) and patients without melanocytic lesions (P < 0.001). 15746042 Human
mart-1 melanoma CONCLUSIONS: Quantitative RT-PCR MART-1 and tyrosinase mRNA analysis cannot be used alone for SN diagnosis because of its poor specificity for melanoma metastasis. 15746042 Human
mart-1 metastases Using the presence of a MART-1 RT-PCR signal to detect patients with metastases, a sensitivity of 100% and a negative predictive value of 100% were achieved when extensive immunohistology was used as reference. 15746042 Human
mart-1 tumor The level of melanocyte-associated mRNA is associated with both tumor thickness and tumor burden as measured histopathologically, suggesting that this may be of prognostic value. 15746042 Human
mart-1 melanoma Median MART-1 and tyrosinase mRNA levels in SNs were significantly different in patients with metastasis compared with patients with BNIs (P < 0.05) and patients without melanocytic lesions (P < 0.001). 15746042 Human
mart-1 tumor However, in approximately one third of cases without RT-PCR evidence of MART-1 expression, extensive histopathologic SN investigation is not necessary, thus substantially reducing the cost of SN analysis. 15746042 Human
mart-1 metastases However, in approximately one third of cases without RT-PCR evidence of MART-1 expression, extensive histopathologic SN investigation is not necessary, thus substantially reducing the cost of SN analysis. 15746042 Human
mart-1 metastases The level of melanocyte-associated mRNA is associated with both tumor thickness and tumor burden as measured histopathologically, suggesting that this may be of prognostic value. 15746042 Human
mart-1 metastasis CONCLUSIONS: Quantitative RT-PCR MART-1 and tyrosinase mRNA analysis cannot be used alone for SN diagnosis because of its poor specificity for melanoma metastasis. 15746042 Human
mart-1 melanoma Eight HLA-A2+ melanoma patients received 4 monthly vaccinations of low-dose CpG 7909 mixed with melanoma antigen A (Melan-A; identical to MART-1) analog peptide and incomplete Freund's adjuvant. 15696196 Human
mart-1 tumors These results demonstrate the possibility of enhancing the immunogenicity of the native MART-1 and other RNA derived from weakly immunogenic tumors in DC-based immunotherapy. 15820257 Human
mart-1 b16 melanoma Immunization with MART-1 melanoma antigen-engineered DC in C57BL/6 mice resulted in the generation of antigen-specific cytotoxic T lymphocytes and in vivo protective responses to the murine B16 melanoma. 15775996 Mouse
mart-1 melanoma Immunization with MART-1 melanoma antigen-engineered DC in C57BL/6 mice resulted in the generation of antigen-specific cytotoxic T lymphocytes and in vivo protective responses to the murine B16 melanoma. 15775996 Mouse
mart-1 melanoma The MCW melanoma cocktail (a mixture of MART-1 [1:500], Melan-A [1:100] and tyrosinase [1:50] monoclonal antibodies) has demonstrated a highly discriminatory immunostaining pattern. 15934808 Human
mart-1 tumor METHODS: The authors validated 21 commonly used antibodies (cytokeratin [CK] 7, CK 20, TTF-1, panCK, vimentin, HMB-45, Mart-1, leukocyte common antigen, chromogranin, synaptophysin, estrogen receptor, progesterone receptor, prostate-specific antigen, pros 15852338 NA
mart-1 melanoma Phase I Study of a Plasmid DNA Vaccine Encoding MART-1 in Patients with Resected Melanoma at Risk for Relapse. 16000957 Human
mart-1 melanoma The safety and immunologic response of a plasmid encoding the MART-1 melanocyte differentiation antigen was evaluated in 12 patients with resected melanoma at risk for relapse. 16000957 Human
mart-1 tumor Some studies have used direct extraction of intact tumor cells from the peripheral blood and others the detection of surrogate markers of circulating melanoma cells, such as tyrosinase or MART-1. 16091200 Human
mart-1 melanoma Some studies have used direct extraction of intact tumor cells from the peripheral blood and others the detection of surrogate markers of circulating melanoma cells, such as tyrosinase or MART-1. 16091200 Human
mart-1 tumor Some tumor cells showed a keratinocytic phenotype (cytokeratins, p63) and others a melanocytic phenotype (HMB-45, MART-1, Melan-A, S100-protein). 16121052 Human
mart1 human tumour Furthermore, we show that fixed E. coli/LLO expressing the well-characterised human melanoma antigen, MART1, efficiently deliver the HLA-A2-restricted MART1(27-35) epitope for processing and presentation on human MoDCs, suggesting the potential of this sy 12767067 Human
mart1 nevus Individual immunoperoxidase-positive cells were also identified within the parenchyma of lymph nodes without capsular nevus (9 LNs with MART1 and 3 LNs with MelanA). 15105646 Human
mart1 tumor We report on 10 patients with resected American Joint Committee on Cancer (AJCC)stage IIA-IIIC melanoma receiving individualized adjuvant peptide vaccinations derived from the melanosomal antigens MelanA/MART1, gp100 and tyrosinase, according to patient t 15665624 Human
mart1 cancer We report on 10 patients with resected American Joint Committee on Cancer (AJCC)stage IIA-IIIC melanoma receiving individualized adjuvant peptide vaccinations derived from the melanosomal antigens MelanA/MART1, gp100 and tyrosinase, according to patient t 15665624 Human
mart1 melanoma We report on 10 patients with resected American Joint Committee on Cancer (AJCC)stage IIA-IIIC melanoma receiving individualized adjuvant peptide vaccinations derived from the melanosomal antigens MelanA/MART1, gp100 and tyrosinase, according to patient t 15665624 Human
mart 1 melanoma The frequency of melanoma cell detection in patients' blood was about 10% higher when the TYR/MART 1 two-marker assay was used. 11254117 Human
mart 1 melanoma The frequency of melanoma cell detection with the TYR/MUC-18 two-marker assay was even higher than the TYR/MART 1 assay, but unfortunately the MUC-18 transcript was also present in about 20% of healthy subjects. 11254117 Human
mart 1 tumour In all investigated patients they assessed circulating tumour cells (melanocytes) in the peripheral blood stream based on the detection of mRNA tyrosinase and marker MART 1. 12181879 Human
mart 1 nodular melanomas In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S 15233017 Human
mart 1 lentigo maligna melanomas In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S 15233017 Human
mart 1 cutaneous malignant melanomas In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S 15233017 Human
mart 1 malignant melanomas In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S 15233017 Human
melan-a sertoli-leydig cell tumors of the ovary However, here we report the presence of immunoreactivity for A103, an antibody to Melan-A, in five adrenocortical adenomas, 16 primary and 13 metastatic adrenocortical carcinomas, four Leydig cell tumors of the testis, and three Sertoli-Leydig cell tumors 9422316 Human
melan-a aml Immunohistochemical stains showed reactivity for actin, but not HMB-45, Melan-A, and tyrosinase (despite reactivity of the patient's renal AML for HMB-45 and Melan-A), perhaps owing to the small size of the lesion and the sometimes focal nature of th 10534179 Human
melan-a ovarian sex cord-stromal tumours Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. 10823140 Human
melan-a ovarian sex cord-stromal tumours AIMS: To assess A103 (melan-A) immunoreactivity in a range of ovarian sex cord stromal tumours and to evaluate it for the differential diagnosis of other neoplasms. 10823140 NA
melan-a histiocytomas To explore the use of immunohistochemistry for this diagnostic problem, we examined the expression of S-100 protein, gp100 (the antigen recognized by HMB-45), tyrosinase (T311), Melan-A (A103), Factor XIIIa (FXIIIa), and CD68 in 10 juvenile xanthogranulom 10871066 Human
melan-a melanoma The identification of melanoma antigenic peptides like Melan-A, gp100 and ras peptides has opened new possibilities in the treatment of malignant melanoma. 11098573 Human
melan-a skin metastases CTL specific for the melanoma Ags melan-A, tyrosinase, and MAGE3 were cloned from the peripheral blood, tumor-infiltrated lymph nodes, and skin metastases of five patients. 10358133 Human
melan-a stromal tumors Finally, the recent availability of markers of ovarian stroma, including Melan-A and inhibin-alpha, has provided a means for the positive identification of ovarian stromal tumors, which can manifest protean histological appearances. 11192073 Human
melan-a melanoma The melan-A immunohistology seems to be more important in the diagnosis of balloon cell melanoma than the classic melanoma antibody HMB 45. 11321731 Human
melan-a balloon cell melanoma The melan-A immunohistology seems to be more important in the diagnosis of balloon cell melanoma than the classic melanoma antibody HMB 45. 11321731 Human
melan-a cell tumour The Melan-A antibody labelled all balloon cell tumours and one signet-ring cell tumour, whereas the anti-tyrosinase antibody was not reactive in any of the tumours. 11578133 Human
melan-a cell tumours The Melan-A antibody labelled all balloon cell tumours and one signet-ring cell tumour, whereas the anti-tyrosinase antibody was not reactive in any of the tumours. 11578133 Human
melan-a malignant melanoma of soft parts Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. 12072203 Human
melan-a epithelioid melanoma Mitf Melan-A, and tyrosinase are sensitive markersfor epithelioid melanoma. 12472287 Human
melan-a invasive breast cancer In this paper a case of a patient with ductal invasive breast cancer with partial melanocytic differentiation was presented, documented by HMB-45 and melan-A reactivity of tumor cells. 12852152 Human
melan-a tumor In this paper a case of a patient with ductal invasive breast cancer with partial melanocytic differentiation was presented, documented by HMB-45 and melan-A reactivity of tumor cells. 12852152 Human
melan-a adrenal tumors We have recently observed a high level of calretinin expression in normal adrenal cortex but not the medulla and therefore evaluated its diagnostic application for adrenal tumors in comparison with inhibin, melan-A, and BCL-2. 12808065 Human
melan-a extraadrenal paragangliomas In this study, 28 adrenal cortical tumors (12 carcinomas, 16 adenomas), 20 pheochromocytomas, and 20 extraadrenal paragangliomas were evaluated for calretinin, inhibin, melan-A, BCL-2, and c-kit expression by standard immunohistochemical assays on paraffi 12808065 NA
melan-a pheochromocytomas In this study, 28 adrenal cortical tumors (12 carcinomas, 16 adenomas), 20 pheochromocytomas, and 20 extraadrenal paragangliomas were evaluated for calretinin, inhibin, melan-A, BCL-2, and c-kit expression by standard immunohistochemical assays on paraffi 12808065 NA
melan-a extraadrenal paragangliomas Extraadrenal paragangliomas showed reactivity with calretinin in 25%, melan-A in 5%, inhibin in 16%, BCL-2 in 38%, and c-kit in 8% of the cases. 12808065 Human
melan-a tumor Tumor cells were negative for Melan-A, tyrosinase, HMB-45, AE1/AE3, cytokeratin (CK) 7, CK8/ 18, CK20, CK903, CAM 5.2, epithelial membrane antigen, smooth muscle actin, desmin, leukocyte common antigen, Bcl-2, CD3, CD20, CD30, CD138, kappa and lambda ligh 15163228 Human
melan-a tumor Immunohistochemically, the tumor cells were positive for HMB-45 and neuron specific enolase but negative for epithelial markers, smooth muscle markers, other neuroendocrine markers, vimentin, melan-A, and S-100 protein. 15252321 Human
melan-a tumor Loading of the tumor cells with Melan-A peptide reversed the resistance to killing, suggesting impaired function of the MHC class I antigen processing and presentation pathway. 15342421 Human
melan-a tumours Immunohistochemical studies were performed on six tumours using monoclonal antibodies (MAb) to S100 protein, tyrosinase (MAb T311), Melan-A (MAb A103), and gp100 (MAb HMB-45), as well as antibodies to five cancer/testis (CT) antigens (MAb CT7-33 to CT7/MA 14646623 Human
melan-a melanoma In order to investigate whether the MAA expression detected on cell cultures established from melanoma patients might relate to the overall survival in these patients, we screened primary cell cultures derived from 37 melanoma metastases for the expressio 15305155 Human
melan-a metastases In order to investigate whether the MAA expression detected on cell cultures established from melanoma patients might relate to the overall survival in these patients, we screened primary cell cultures derived from 37 melanoma metastases for the expressio 15305155 Human
melan-a melanoma MAA expression detected by PCR was found at a high percentage in evaluated melanoma cell lines: 25 of 28 (89%) were positive for Melan-A, 22 of 28 (79%) were positive for tyrosinase, 26 of 28 (93%) were positive for gp-100, and 18 of 28 (64%) were positiv 15305155 Human
melan-a melanoma in situ Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. 15365366 Human
melan-a pigmented actinic keratosis Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. 15365366 Human
melan-a metastatic tumors Melan-A, also known as MART-1, is an additional melanocytic marker and has proved to be useful in identifying metastatic tumors of melanocytic origin. 15365366 Human
melan-a pigmented actinic keratosis In this study we evaluated Melan-A expression in ten unequivocal cases of pigmented actinic keratosis and compared the staining pattern with that of S-100, HMB-45, and tyrosinase. 15365366 NA
melan-a actinic keratosis Even areas of normal skin adjacent to the actinic keratosis featured prominent staining of Melan-A, but only inconsistent labeling of intraepidermal melanocytes with S-100, HMB-45, and tyrosinase. 15365366 Human
melan-a melanoma Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells. 15528338 Human
melan-a melanoma The melanoma-associated protein Melan-A contains the immunodominant CTL epitope Melan-A(26/27-35)/HLA-A*0201 against which a high frequency of T lymphocytes has been detected in many melanoma patients. 15528338 Human
melan-a melanoma Using a tumor-reactive CTL clone, we confirmed that the recognition of melanoma cells expressing an N-terminally extended intermediate of Melan-A is inefficient. 15528338 Human
melan-a metastatic melanoma We studied the effect of immunohistochemistry (IHC) on mRNA recovery from labeled cells after microdissection from both frozen and formalin-fixed, paraffin-embedded (FFPE) sections, using Melan-A and Ki-67 staining in lymph nodes with metastatic melanoma 15538113 NA
melan-a tumors Tumors expressed S-100 protein (8 of 8), Melan-A (4 of 8), HMB-45 (8 of 8), and microphthalmia transcription factor (8 of 8) and lacked pancytokeratin (8 of 8) and smooth muscle actin (8 of 8). 15577676 Human
melan-a desmoplastic nevi Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. 15618925 Human
melan-a desmoplastic melanoma Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. 15618925 Human
melan-a blue nevi CONCLUSION: The sclerotic/desmoplastic and hypopigmented blue nevi were uniformly positive for Melan-A, while the vast majority of DMM were negative in their spindle cell compartments. 15618925 Human
melan-a spindle-cell tumor The pathological examination revealed a picture of spindle cell tumor that was strongly positive for S-100 protein stain, and non-reactive for CD34, CD117, actin, HHF-35, desmin, melan-A and HMB-45, consistent with gastric schwannoma. 15720074 Human
melan-a schwannoma The pathological examination revealed a picture of spindle cell tumor that was strongly positive for S-100 protein stain, and non-reactive for CD34, CD117, actin, HHF-35, desmin, melan-A and HMB-45, consistent with gastric schwannoma. 15720074 Human
melan-a primary cutaneous melanoma From 139 patients with primary cutaneous melanoma who underwent sentinel lymphadenectomy, a total of 235 SLN were assessed for Melan-A and tyrosinase expression by real-time quantitative RT-PCR. 15737205 Human
melan-a atypical fibroxanthoma Immunohistochemical stains were positive for CD68 and vimentin and negative for Melan-A or human melanoma black (HMB)-45, S-100 protein, pancytokeratin, and actin, consistent with atypical fibroxanthoma. 15769283 Human
melan-a melanoma Eight HLA-A2+ melanoma patients received 4 monthly vaccinations of low-dose CpG 7909 mixed with melanoma antigen A (Melan-A; identical to MART-1) analog peptide and incomplete Freund's adjuvant. 15696196 Human
melan-a melanoma We show here that, in melanoma cells, Melan-A associates with two homologous to E6-AP C-terminus (HECT)-E3 ubiquitin ligases, NEDD4 and Itch, and is ubiquitylated. 15703212 Human
melan-a metastatic cancer Tyrosinase expression was evaluated together with standard cytology and ICC (anti-S100, HMB-45 and Melan-A antibodies) in biological fluid samples collected from 17 melanoma patients according to the site of metastatic involvement or clinical suspicion (e 15832768 Human
melan-a icc Tyrosinase expression was evaluated together with standard cytology and ICC (anti-S100, HMB-45 and Melan-A antibodies) in biological fluid samples collected from 17 melanoma patients according to the site of metastatic involvement or clinical suspicion (e 15832768 Human
melan-a melanoma Tyrosinase expression was evaluated together with standard cytology and ICC (anti-S100, HMB-45 and Melan-A antibodies) in biological fluid samples collected from 17 melanoma patients according to the site of metastatic involvement or clinical suspicion (e 15832768 Human
melan-a tumour Immunohistochemistry revealed an intense labelling of tumour cells for vimentin, and a partial labelling for neuron-specific enolase, S100 protein, and Melan-A. 15893992 Human
melan-a melanoma The MCW melanoma cocktail (a mixture of MART-1 [1:500], Melan-A [1:100] and tyrosinase [1:50] monoclonal antibodies) has demonstrated a highly discriminatory immunostaining pattern. 15934808 Human
melan-a epithelioid leiomyosarcoma Histological findings, including immunohistochemical study using desmin, SMA, cytokeratin, S-100, HMB-45, vimentin, melan-A, and CD68, led to a diagnosis of epithelioid leiomyosarcoma of the uterine cervix. 15890394 Human
melan-a tumor Immunohistochemically, the tumor cells were positive for vimentin, S-100 protein, calretinin, inhibin-alpha, melan-A, and CD10, and type IV collagen and laminin were observed in the extracellular matrix around the tumor cells. 15943795 Human
melan-a leydig cell tumor The distributions of melan-A, CD10, and mitochondria were characteristically patchy; in contrast, they were diffusely distributed in the cytoplasm in a control case of Leydig cell tumor. 15943795 Human
melan-a sertoli cell tumor The differences in immunostaining patterns for melan-A, CD10, and mitochondria as well as positivity for S-100 protein-beta might be useful diagnostic hallmarks of large cell calcifying Sertoli cell tumor for discrimination from Leydig cell tumor. 15943795 Human
melan-a leydig cell tumor The differences in immunostaining patterns for melan-A, CD10, and mitochondria as well as positivity for S-100 protein-beta might be useful diagnostic hallmarks of large cell calcifying Sertoli cell tumor for discrimination from Leydig cell tumor. 15943795 Human
melan-a melanoma We investigated the expression of five MAA - Melan-A/MART-1, tyrosinase, gp100, MAGE-1 and MAGE-3 - by means of FACS analysis in 50 melanoma cell cultures and compared them to the cultures of human foreskin-derived melanocytes and melanoma cell line UKRV- 15946236 Human
melan-a melanoma Melan-A, tyrosinase and gp100 expression was frequently reduced in melanoma cell cultures, compared to that in foreskin melanocytes, whereas MAGE-1 and MAGE-3 expression showed variable degree of upregulation, compared to that in foreskin melanocytes. 15946236 Human
melan-a primary tumours Finally, we demonstrate that brain metastasis-derived cell cultures significantly overexpress Melan-A and MAGE-3, compared to primary tumours and other metastatic sites (P-value range: 0.05-0.001). 15946236 Human
melan-a primary tumours Analysing samples derived from the same patient but each at a different time point, we show that MAA expression profile changes over time either in positive (increase) or in negative (decrease) direction. 15946236 Human
melan-a mucosal melanomas HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas. 16138892 Human
melan-a tumor Some tumor cells showed a keratinocytic phenotype (cytokeratins, p63) and others a melanocytic phenotype (HMB-45, MART-1, Melan-A, S100-protein). 16121052 Human
melan-a bcc Immunohistochemical studies with S100 protein, HMB-45, and Melan-A antibodies showed the melanocytic component in the epidermis and dense clusters of "atypical" melanocytes in the dermal nests of BCC. 16121053 Human
melan a necrosis However, initial follow-up surgical pathology reported only "extensive coagulative necrosis, no viable tumor seen." Subsequent immunohistochemical stains (cytokeratins (AE1/AE3), HMB45, S100, and Melan A) demonstrated the presence of metastatic 11477713 Human
melan a hyperplastic A total of 200 formalin-fixed, paraffin-embedded canine normal tissues and hyperplastic and neoplastic lesions of the adrenal gland, testis, and ovary were immunohistochemically tested for Melan A with antibody A103. 11478605 Human
melan a basal cell tumor Although less sensitive than S100 protein, Melan A is more specific for melanoma and is useful in differentiating feline cutaneous melanoma from the more common pigmented basal cell tumor. 12102204 others
melan a hepatocellular carcinomas Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. 14663359 Human
melan a adrenocortical neoplasms Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. 14663359 Human
melan a adrenocortical neoplasms Thirty-one of the 32 adrenocortical neoplasms showed strong and diffuse granular cytoplasmic staining for Melan A. 14663359 Human
melan a tumor Melan A and tyrosinase positivity (P = 0.0195), smooth muscle actin positivity (P = 0.0328), tumor size (P = 0.0297), and tumor thickness (P = 0.0419) were significantly associated with local progression-free survival. 14765268 Human
melan a tumour The tumour was identified as a malignant melanoma immunohistochemically by positive reactions for gp100 (HMB45), melan A, and MiTF. 15011002 Human
melan a nodular melanomas In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S 15233017 Human
melan a lentigo maligna melanomas In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S 15233017 Human
melan a cutaneous malignant melanomas In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S 15233017 Human
melan a malignant melanomas In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S 15233017 Human
melan a tumor The tumor cells strongly expressed S100 protein, gp100 (HMB-45), melan A, and tyrosine antibodies (Fig. 2C,D). 15485534 Human
melan a cutaneous melanoma An osteoid variant of cutaneous melanoma in a dog detected by s100 and melan a markers. 15610483 others
melan a tumours Amelanotic tumours are sometimes difficult to recognize as they require immunohistochemical evaluation for an adequate diagnosis and we have used anti-vimentin, S100, and melan A antibodies for identification. 15610483 Human
melan a amelanotic melanomas Melan A is less sensitive but more specific than S100 in identifying amelanotic melanomas. 15610483 others
melan a tumour This tumour was positive for vimentin, S100 and melan A, including the areas of osteoid. 15610483 others
melan a tumor Immunohistochemically, the tumor cells showed positive reactions with antibodies against HMB-45, melan A, CD-68, muscle-specific actin, and, rarely, smooth muscle actin. 15792132 Human
melan a tumor EXPERIMENTAL DESIGN: In sentinel lymph nodes from 358 melanoma patients, we prospectively compared the rates of tumor cell detection between immunocytochemistry using HMB45 and Melan A antibodies on disaggregated lymph node samples and standard histopatho 16061857 Human
melan a melanoma EXPERIMENTAL DESIGN: In sentinel lymph nodes from 358 melanoma patients, we prospectively compared the rates of tumor cell detection between immunocytochemistry using HMB45 and Melan A antibodies on disaggregated lymph node samples and standard histopatho 16061857 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.